CURRICULUM VITAE 2015

CURRICULUM VITAE
John C. Ruckdeschel, M.D.
PERSONAL DATA:
Date and Place of Birth: January 5, 1946, Newport, Rhode Island
Residence: 10838 Willow Heights Drive
Las Vegas, NV 89135
313-485-7808
Email: jruckdeschel@me.com, jruckdeschel@synergyccn.com
EDUCATIONAL EXPERIENCE:
Oceanside High School, Oceanside, NY - Regents Diploma (honors)1963
Rensselaer Polytechnic Institute, Troy, NY - B.Sc. Biology 1967
Albany Medical College, Albany, NY - M.D. 1971
Foundation for Advanced Education in the Sciences, NIH 1973, 1983 – 1984
Intermountain Advanced Training Program in Clinical Practice Improvement
Institute for Health Care Delivery Research, Salt Lake City, UT 2012
PROFESSIONAL EXPERIENCE:
Current Positions:
Attending Physician, Synergy Cancer Center of Nevada
CEO, Ruckdeschel Consultants,LLC
Chief Medical Officer, EMX Advanced Technologies
Professor of Medicine (Adjunct), University of Utah, Huntsman Cancer Institute, Salt Lake City, UT
Editor (United States)Cochrane Lung Cancer Group
Vice-president, Red Rock Audubon Society
Previous Positions:
Medical Director, Oncology Clinical Program, Intermountain Healthcare, Salt Lake City, UT
2012-2014
Chair, Utah Cancer Action Network 2013-2014
Professor of Medicine University of Utah, Huntsman Cancer Institute,Salt Lake City, UT
Professor of Medicine, University of Nevada School of Medicine 2009-2011
Chair, Patient Services Committee, Health Advisory Board of the University Medical Center of
Southern Nevada 2010-2011
Chief Executive Officer and Director, Nevada Cancer Institute 2009-2011
VP Health Affairs/Dean; University of NV School of Medicine Search Committee 2010-2011
President and Chief Executive Officer, Barbara Ann Karmanos Cancer Institute 2002-2009
Associate Dean, Cancer Affairs, Wayne State University School of Medicine 2002-2009
Professor of Medicine and Oncology, Wayne State University School of Medicine 2002-2009
Board of Directors, Michigan Cancer Consortium 2002-2009
Senior VP - Cancer, The Detroit Medical Center: President, The Cancer Hospital 2002-2005
Interim Chair, Radiation Oncology Wayne State University School of Medicine 2002-2003
Professor of Oncology and Medicine, University of South Florida College of Medicine 1991-2002
Director and Chief Executive Officer, H. Lee Moffitt Cancer Center, Tampa, FL 1991-2002
Case Research Professor, University of Tampa College of Business 1996-2002
President, Florida Division, American Cancer Society 2001-2002
Director, Joint Ctr for Cancer and Blood Disorders Albany Medical College, Albany, NY1989
1991
Professor of Medicine (1985 - 1991); Associate Professorof Medicine (1979 - 1985); 1976-1991
Assistant ProfessorofMedicine, (1976 - 1979); Albany Medical College, Albany, NY
Visiting Professor, Foundation for Promotion of Cancer Research, National Cancer Center,
Tokyo, Japan 1990
Visiting Scientist, NCI - Navy Medical Oncology Branch, NCI, Bethesda, Maryland 1983-1984
Senior Assistant Resident - Medicine, Beth Israel Hospital, Boston,MA 1975-1976
Staff Associate,NCI - Baltimore Cancer Research Center, Baltimore, MD 1972-1975
Straight Medical Intern, Johns Hopkins Hospital, Baltimore, MD 1971-1972
04 December 2014

John C. Ruckdeschel,M.D.
HONORS:
Distinguished John Hopkins School of Medicine Alumni Award 2009
Michigan Cancer Consortium Spirit of Collaboration Award 2007
Hour Magazine Top Doctors in Detroit 2006
Best Doctors in America 1993 -
America's Top Doctors 2000 -
Honorary Member, USF Golden Key International Honor Society 2001
Distinguished Southern Oncologist Award 2001
Tampa Bay Magazine’s “Doctors Chosen by Doctors” 2001
Exemplary Alumni Award, Albany Medical College, Albany, NY 2000
11th Annual Florida Medical Business Healthcare Physician Business Leadership Award 2000
Town and Gown Community Service Award 1999
The Medical Business Top 25: The Most Influential Physicians in Tampa Bay 1998
Bellwether Award for Lifetime Achievement 1997
Who’s Who in Medicine and Healthcare 1996
Rensselaer Alumni Association Fellows Award - Biology 1996
Brooks Brothers Man of the Year 1994
Excel Award for Excellence in Communication Leadership 1994
Who’s Who in Science and Engineering 1991
Sigma Xi 1986 -2002
American Medical Association,Physicians Recognition Award 1974 -
Alpha Omega Alpha (Medicine) 1971
Henry B. Barnet, Jr., Commencement Award for Significant Contribution in Cancer 1971
S. Oakley Vander Poel Commencement Award for Best Clinical Exam in Medicine 1971
Who’s Who Among Students in American Colleges and Universities 1967
Pi Delta Epsilon (Journalism) 1966
PROFESSIONAL ORGANIZATIONS:
Center and Institute Advisory Committee (CIAC), Wayne State University Division of Research
2004-2009
U.S. National Committee for the International Union Against Cancer (USNC/UICC)
American Joint Committee on Cancer 2000-2008
National Comprehensive Cancer Network Board of Directors 1998-2002
Executive Committee (2000 - 2002)
National Coalition for Cancer Research (NCCR) Board of Directors 1999-2006
Council of Teaching Hospitals (COTH) - American Association of Medical Colleges 1997-2002
American College of Chest Physicians
Fellow 1993 -
American Association of Cancer Institutes 1992 - 2009
Board of Directors (1997 - 1999); Legislative Committee (2001 - 2009)
American Medical Association 1992 -
American College of Physician Executives 1988 -
Lung Cancer Study Group 1982-1990
(Executive Officer 1986 - 1990)
American Cancer Society 1977 - 2002
Junior Faculty Clinical Fellow (1977 - 1980);
National Advisory Committee on Psychosocialand Behavioral Research (1986 - 1989;
Chair 1989);
Board of Directors, Greater Tampa (1992 - 1997);
Chair, Research Committee of Florida Division (1999 - 2000);
Florida Division Board of Directors (1997 - 2002); Executive Committee (1998 - 2002);
Medical Vice President of Florida Division (1999 - 2000);
President, Florida Division (2001 - 2002)

American Association for Cancer Education 1977 -
International Association for the Study of Lung Cancer 1977 -
American Society of Clinical Oncology 1977 -
Publications Committee (2004 - )
Cancer Education Committee (2005 – Chair Health Services Research Track, 2006-2008)
American Federation for Clinical Research 1977 - 1986
Councilor, Eastern Section (1981 - 1986)
American Association for Cancer Research 1976 -2009
Finance Committee (2001 - 2005
American College of Physicians 1975 -
Fellow (1979 - )
LICENSURE:
New York (inactive), Maryland (inactive),Massachusetts (inactive),Florida (ME0068653), Michigan
(inactive) Nevada (13104), Utah (8192686-1205)
MILITARY:
United States Public Health Service 1972 – 1975
BOARDS:
American Board of Internal Medicine, Certified 6/76, no. 53664
Medical Oncology, Certified 10/77
GRANT SUPPORT:
Prior Funding:
NIH: NCI Outcomes of Triaged Family Care in Advanced Cancer 5R01CA107383-04 $9,758 (annual
direct) 09/28/04 - 05/31/09 (PI:Northouse)
NIH: NCI Cancer Center Support Grant 5P30CA022453-26 $1,607,780 (annual direct) 09/08/97 –
11/30/90 (PI:Ruckdeschel
NIH: NCI Cancer Center Support Grant – Supplement: Cryo-immunotherapy for Lung Tumors
2P30CA022453-24 $2,500,000 (annual direct) 12/01/04 – 11/30/09 (PI:Ruckdeschel)
NIH: NCI Cancer Center Support Grant – Supplement : caBIG Technology Assessment and
Implementation
EPA National Center for Vermiculite and Asbestos Related Cancers 83299701-0 $967,000 (total award)
09/01/06 –08/31/08 (PI: Ruckdeschel)
DOD National Oncogenomic and Molecular Imaging Center (NOMIC) ERMS 07078003 $1,571,186
04/01/08 – 03/31/13 (PI Ruckdeschel)
Threshold Pharmaceuticals, Inc An Open-Label, Phase II Study to Evaluate the Safety and Efficacy of
Glufosfamide in the Treatment of Patients with Recurrent Sensitive Small Cell Lung Carcinoma THCR-
304 $108,693 (total)11/01/06 – 11/08/07 (PI:Ruckdeschel)
NCI: Parental role in Pediatric Cancer Pain and Survivorship. 5R01CA10027-01 - $866,105 09/19/03 –
08/31/07(PI Albrecht)
NCI: Effects of Physician Communication on Patient Accrual. 7R01CA75003-01A3 $268,204 (annual
direct),04/01/01 - 03/31/06. Dr. Teri Albrecht, PI
NCI: Biopsychosocial Processes and Treatment Decision Making. 1R21CA113220-01 $75,000 (annual
direct),09/30/04 – 09/29/06. Dr. Teri Albrecht, PI.
CDC Cancer Prevention and Control Earmarks (National Center for Vermiculite and Asbestos Related
Cancers)
ACS: Institutional Research Grant. ACS 93-032-07-02 - $120,000 (annual direct). 07/01/00 - 06/30/03. PI.
NCI: Moffitt Cancer Center PRCC Partnership. $125,000 (annual direct). P20CA91353-01, 5/18/01-
4/30/04. PI.
NCI: Cancer Center Support Grant. P30 CA 76292-05 - $1,647,244 (annual direct). 03/06/01-01/31/05. PI.
NCI: Project Link: Leaders in New Knowledge. Supplement to P30 CA76292 - $72,424 (annual direct).
05/18/01-01/31/06. PI.
NIH: Mouse Barrier Facility. C06 RR017510-01 - $2,000,000 (annual direct). 9/01/02-8/31/04. PI.

EDITORIAL/REVIEW ACTIVITIES:
Editorial:
Editor in Chief: Evidence-Based Oncology (1999 - 2002)
Co-Editor: Textbook of Thoracic Oncology, I and II Editions
Editorial Board: Chest
Current Treatment Options in Oncology
Medical Oncology
Social Marketing Quarterly
Journal of Cancer Education
Cancer Control: Journal of the Moffitt Cancer Center
Section Editor for Lung and Mediastinum – Current Opinion in Oncology
Reviewer:
Annals of Internal Medicine
Cancer Chemotherapy and Pharmacology
Cancer Research
Chest
Journal of Clinical Oncology
Journal of the National Cancer Institute
Journal of Neuro-Oncology
Journal of Thoracic Oncology
Investigational New Drugs
Preventive Medicine
Proceedings, National Academy of Sciences (U.S.A.)
Social Science and Medicine
NATIONAL CANCER INSTITUTE - SITE VISITOR - AD HOC REVIEWER:
NIH-Support Centers for Population Health and Health Disparities (P50) Co-chair 2009
NIH Loan Repayment Program Awards 2008, 2009
MD Anderson Cancer Center Support Grant 2003
Biological Mechanisms of PsychosocialEffects on Disease (BiMPED) 2002
Lung Progress Review Group (PRG) Co-Chair 2000
NCI/ACS Conference on Lung Screening, Co-Chair 2000
University of Rochester Core Grant (R. Abraham) 1999
Rapid Access to Intervention Development (RAID) Reviewer 1998
Program Project Review Committee (Subcommittee C) 1994
Cornell University Program Project (F. Barany) - Chairman 1994
Yale Cancer Center Support Grant (V. DeVita) 1994
Behavioral Medicine Study Section (Ad Hoc Reviewer) 1991, 1993
Non-Small Cell Lung Cancer Strategy Meeting (Ad Hoc Reviewer) 1990, 1992
University of Tennessee Program Project (H. Schuller) - Chairman 1992
Specialized Program of Research Emphasis - Prostate Cancer 1992
Specialized Program of Research Emphasis - Lung Cancer 1992
Special Review Committee - Community Clinical Oncology Program 1990
Dana Farber Cancer Center Program Project (E. Frei) 1990
Memorial Sloan-Kettering Cancer Center Program Project (J. Bertino) 1989
Middle Atlantic Oncology Program 1985
Piedmont Oncology Group (R. Capizzi) 1985
Catholic Medical Center Program Project (D. Martin) 1979
Lung Cancer Study Group (E. Holmes) 1978
External Advisor/Reviewer:
Samuel Ochsin Cancer Center, Cedars Sinai 2010-

University of Hawaii 2007-2008
UT San Antonio/CTRC, Chair 2007-2010
University of Oklahoma Cancer Center 2005 -2006
Penn State Cancer Center (Chair) 2003 -2010
Behavioral Review Panel for the Nebraska Cancer & Smoking Disease Research Program 2001 -
USC/Norris Comprehensive Cancer Center External Advisory Committee 1999 -2002
Rensselaer Polytechnic Institute College of Science External Advisory Board 1999 -2010
American Institute of Biological Sciences (Army, DOD reviews) 1997 - 2009
Wake Forest Cancer Center External Advisory Board, (Chair 1999 -) 1997 - 2009
U.S. Army Medical R&D Command Breast Cancer Research Program (Reviewer) 1994 -
Illinois Cancer Council External Advisory Board 1989 - 1992
Tobacco Related Disease Research Program Study Section (California) 1990 -
VA Merit Review Program 1989 - 1993
ACS Psychosocialand Behavioral Review Committee, (Chair 1989 -) 1986 – 1989
COMMUNITY:
Health Advisory Board, University Medical Center of Southern Nevada 2010-
Clark County Committee on Priorities 2009-2010
Greater Detroit Area Health Council 2007-2009
Board of Directors, University Liggett School 2006-2009
Wayne County Health Authority; Provider Advisory Committee (co-chair) 2005 -2007
Community Advisory Board, Junior League of Tampa 2002
Committee of 100 Steering Committee of Tampa Chamber of Commerce 2001 - 2002
Sun Trust Bank Board of Directors and Trust Committee of the Board 2000 - 2002
Jesuit High School Board of Trustees 2000 - 2002
Chair, Health/Bio-Medical Committee of the Tampa Chamber of Commerce 1999
Sacred Heart Church, General Chair of Capital Campaign 1998
Jesuit High School Foundation Board of Directors 1998 - 2000
Leukemia Society of America, Suncoast Chapter Board of Trustees 1995 - 1998
West Sand Lake Volunteer Fire Department, West Sand Lake, NY
President 1981 - 1983, Line Officer 1982 - 1983, 1985 - 1986 1979 - 1991
Sand Lake Ambulance, West Sand Lake, NY 1984 - 1991
Board of Directors 1984 - 1985, Line Officer 1985 - 1987, Board President 1989 - 1991
President, Board of Directors, United Urban Ministry of Troy, NY 1976 - 1980
Staff Physician, People’s Free Medical Clinic, Baltimore, MD 1972 - 1975
PUBLICATIONS - PEER REVIEWED
1. Ruckdeschel JC, Codish SD, Stranahan A, McKneally MF. Postoperative empyema improves survival
in lung cancer. Documentation and analysis of a natural experiment. N Engl J Med. 1972;287:1013-7.
2. Ruckdeschel JC, Peters T, Lee KT. Fibrinogen catabolism in rats fed thrombogenic diets.
Atherosclerosis.1972;16:277-85.
3. Graziano KD, Ruckdeschel JC, Mardiney Jr MR. Cell associated immunity to measles (rubeola): the
demonstration of in vitro lymphocyte tritiated thymidine incorporation in response to measles complement
fixation antigen. Cellular Immunol. 1975;15:247-359.
4. Ruckdeschel JC, Graziano, KD, Mardiney Jr MR. Additional evidence that the cell associated immune
systemis the primary host defense against measles (rubeola). Cell Immunol. 1975;17:11-18.
5. Ruckdeschel JC, Chang P, Martin RG, Byhardt RW, O’Connell MJ, Sutherland JC, Wiernik PH.
Radiation-related pericardial effusions in patients with Hodgkin’s disease.Medicine (Baltimore).
1975;54:245-59.
6. Byhardt RW, Brace K, Ruckdeschel JC, Chang P, Martin RW, Wiernik PH. Dose and treatment factors
in radiation related pericardial effusion associated with the mantle technique for hodgkin’s disease.Cancer.
1975;35:795-802.
7. Martin RW, Ruckdeschel JC, Chang P, Byhardt RW, Bouchard P, Wiernik PH. Radiation-related

pericarditis. Am J Cardiol. 1975;35:216-20.
8. Dummire C, Ruckdeschel JC, Mardiney Jr MR. Suppression of in vitro lymphocyte responsiveness to
PPD by measles virus: a re-exploration of the phenomenon. Cell Immunol. 1975;20:205-17.
9. Drake WP, Porkorney DR, Ruckdeschel JC, Levy CC, Mardiney Jr MR. A white blood cell
ribonuclease assay forthe monitoring of malignancy. J Natl Cancer Inst. 1975;54:1475-78.
10. Ruckdeschel JC, Kramarsky B, Mardiney Jr MR. Mycoplasma contamination of membrane associated
measles antigens.Inability to demonstrate in vitro lymphocyte responsiveness to measles. Cell Immunol.
1975;20:110-16.
11. Ruckdeschel JC, Schimpff SC, Smyth AC, Mardiney Jr MR. Correlation of susceptibility to herpes
zoster with impaired cell associated immunity to the varicella-zoster virus in patients with hodgkin’s
disease.Am J Med. 1977;62:77-85.
12. Ruckdeschel JC, Mardiney Jr MR. The demonstration of cell associated immunity to viruses.In vitro
lymphocyte responsiveness to varicella-zoster antigen. J Immunol Methods.1976;13:131-43.
13. Ruckdeschel JC, Doukas J, Drake WP, Mardiney Jr MR. Application of laser cytometry to the analysis
of immunologically induced in vitro lymphocyte blastogenesis.Transplantation.1977;23:396-403.
14. Doukas J, Ruckdeschel JC, Mardiney Jr MR. Quantitative and qualitative analysis of human peripheral
lymphocyte proliferation to specific antigen in vitro by use of the helium neon laser. J Immunol Methods.
1977;15:229-38.
15. Mardiney Jr MR, Ruckdeschel JC. Inhibition of in vitro lymphocyte response by measles virus
antigen: a reply [letter]. Cell Immunol. 1977;28:229.
16. Hahn DM, Schimpff SC, Ruckdeschel JC, Wiernik PH. Single-agent therapy for renal cell carcinoma:
CCNU, vinblastine, thiotepa, or bleomycin. Cancer Treat Rep. 1977;61(8):1585-7.
17. Lempert N, MacDowell RT, Karmody A, Knight E, Cunningham TJ, Sponzo R, Horton J, Ruckdeschel
JC. Vascular access for cancer chemotherapy. Cancer. 1979;43:1934-6.
18. Caradonna R, Paladine W, Ruckdeschel JC, Goldstein JC, Olsen JE, Jaski JW, Silvers SA, Hillinger S,
Horton J. Methotrexate, bleomycin and high dose cis-platinum for advanced epidermoid carcinoma of the
head and neck. Cancer Treat Rep. 1979;63:489-91.
19. Ruckdeschel JC, Baxter DH, McKneally MR, Killan DA, Lunia SL, Horton J. Sequential radiotherapy
and adriamycin in the management of bronchogenic carcinoma: the question of additive toxicity. Int J
Radiat Oncol Biol Phys. 1979;5:1323-8.
20. Ruckdeschel JC, Lininger L, Brzyski H, Miani M, Becker J. Serial quantitation of in vitro lymphocyte
responsivenessto Concanavalin-A. Transplantation. 1979;28(3):203-6.
201 Ruckdeschel JC, Caradonna R, Paladine WJ, Hillinger SM, Horton J. Small cell anaplastic carcinoma
of the lung: changing concepts and emerging problems. CA Cancer J Clin. 1979;29:84-95.
22. Blanchard C, Ruckdeschel JC, Cohen RE, Horton J, McSharry J, Shaw E. Attitudes towards cancer. I:
the impact of a comprehensive oncology course on second year medical students. Cancer. 1981;47:2756-62.
23. Lunia SL, Ruckdeschel JC, McKneally MF, Killam E, Baxter D, Kellar S, Ray P, McIlduff J, Lininger
L, Chodos R, Horton J. Non-Invasive evaluation of mediastinal metastases in bronchogenic carcinoma: a
prospective comparison of chest radiography and gallium-67 scanning.Cancer. 1981;47:672-9.
24. Rodichok LD, Harper GR, Ruckdeschel JC, Price A, Roberson G, Barron KD, Horton J. Early
diagnosis of spinal epidural metastases.Am J Med. 1981;70:1181-7.
25. Ruckdeschel JC, Mehta CR, Salazar OM, Cohen M, Vogl S, Koons LS, Lerner H. Chemotherapy of
inoperable non-small cell bronchogenic carcinoma. Cancer Treat Rep. 1981;65:965-72.
26. Ruckdeschel JC, Mehta CR, Salazar OM, Cunningham TJ, Creech RH, Sponzo RW. Chemotherapy
for metastatic non-small cell bronchogenic carcinoma: EST 2575 generation III, HAM vs CAMP. Cancer
Treat Rep. 1981;65:959-63.
27. Brandman J, Ruckdeschel JC, O’Donnell M, Horton J. Rapid tumor necrosis leading to serious
pulmonary infections in patients treated intensively for small cell cancer of the lung. N Y State J Med.
1981;81:1332-4.
28. Ruckdeschel JC, McKneally MF, Baxter DH, Devore C, Kellar S, Killam D, Caradonna R, Sedransk
N, McIlduff J, Horton J. Regional immunotherapy has a detrimental effect on the response to combined
irradiation and chemotherapy in locally advanced non-small cell bronchogenic carcinoma. Cancer Immunol
Immunother. 1981;11:277-82.
29. Ferraro JA, Horton J, Weissman C, Ruckdeschel JC, O’Donnell M, Ludlum D. Treatment of advanced
colorectal carcinoma with AMSA. Cancer Treat Rep. 1981;65:345-7.
30. Cohen RE, Ruckdeschel JC, Blanchard CG, Rohrbaugh M, Horton J. Attitudes towards cancer. II: a

comparative analysis of cancer patients,medical students,medical residents,physicians and cancer
educators.Cancer. 1982;50:1218-23.
31. Ruckdeschel JC, Lea JW, Brown S, Horton J. Content-bias in the neoplastic-related items of the
national board of
medical examiners part II examination. Med Pediatr Oncol. 1982;10:269-74.
32. Ettinger SD, Day R, Ferraro JA, Ruckdeschel JC, Woll JE, Vogl SE. A phase II study ofAMSA (NSC
249992) and neocarzinostatin (NSC 157365) in non-small cell bronchogenic carcinoma: an Eastern
Cooperative Oncology Group study.Am J Clin Oncol. 1983;6:167-70.
33. Ahles TA, Blanchard EB, Ruckdeschel JC. The multidimensional nature of cancer-related pain. Pain.
1983;17:277-88.
34. Blanchard CB, Ruckdeschel JC, Blanchard EB, Arena JG, Saunders NL, Malloy ED. Interactions
between oncologists and patients during rounds.Ann Intern Med. 1983;99:694-9.
35. Ahles T, Ruckdeschel JC, Blanchard EB. Cancer-related pain. I: prevalence in an outpatient setting as
a function of stage of disease and type of cancer. J PsychosomRes. 1984;28:115-9.
36. Zimmerman MS, Ruckdeschel JC, Hussain M. Chemotherapy-induced interstitial pneumonitis during
treatment of small cell anaplastic lung cancer. J Clin Oncol. 1984;2:396-405.
37. Ahles T, Ruckdeschel JC, Blanchard EB. Cancer-related pain. II: assessment with visual analogue
scales. J PsychosomRes. 1984;28:121-4.
38. Arsenau JC, Wolter JM, Juperminc M, Ruckdeschel JC. A phase II study of bruceantin (NSC-165,
563) in advanced malignant melanoma. Invest New Drugs. 1983;1:239-42.
39. Creech RH, Tritchler D, Ettinger DS, Ferraro JA, Ruckdeschel JC, Vogl SE, Woll J. Phase II study of
PALA amsacrine, teniposide and zinostatin in small cell lung carcinoma (EST-2579). Cancer Treat Rep.
1984;68:1183-4.
40. Spiers ASD, Ruckdeschel JC, Horton J. Effectiveness of pentostatin (2’-deoxyoformycin) in refractory
lymphoid neoplasms. Scand J Haematol. 1984;32:130-4.
41. Ruckdeschel JC, Day R, Weissman CH, Stolbach LL, Creech RH. Chemotherapy for metastatic non-
small cell bronchogenic carcinoma: cyclophosphamide, doxorubicin and etoposide versus mitomycin-
vinblastine (EST 2575, generation IV). Cancer Treat Rep. 1984;68:1325-9.
42. Ruckdeschel JC, Finkelstein D, Creech RH, Mason BA. Chemotherapy for metastatic non-small cell
bronchogenic carcinoma: EST 2575, general V: a randomized comparison of four cisplatin-containing
regimens. J Clin Oncol. 1985;3:72-9.
43. Vogl SE, Camacho F, Berenzweig M, Ruckdeschel JC. Chemotherapy for esophagealcancerwith
mitoguanazone, methotrexate, bleomycin and cisplatin. Cancer Treat Rep. 1985;69:21-3.
44. O’Donnell MR, Ruckdeschel JC, Baxter D, McKneally MF, Caradonna R, Horton J. Intensive
induction chemotherapy for small cell anaplastic carcinoma of the lung. Cancer Treat Rep. 1985;69:571-5.
45. Bonomi P, O’Reilly W, Vogl SE, Ruckdeschel JC, Stolbach L, Bunting N, Creech RH. Intensive
induction treatment of small cell bronchogenic carcinoma with cyclophosphamide,methotrexate and
etoposide.Cancer Treat Rep.1985;69:1007-9.
46. Ettinger DS, Finkelstein DM, Harper GR, Ruckdeschel JC, Chang AY, Camacho FJ, Marsh JC, Silber
R, Wolter JM. Phase II study of mitoxantrone, aclarubicin and diaziquinone in the treatment of non-small
cell lung carcinoma: an Eastern Cooperative Oncology Group study.Cancer Treat Rep. 1985;69:1033-4.
47. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RA, Mason RC, Joss BA, Vogl S. A
randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol.
1986;4:14-22.
48. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small cell lung
cancer: anEastern Cooperative Oncology Group study.J Clin Oncol. 1986;4:702-9.
49. Blanchard CG, Ruckdeschel JC, Fletcher BA, Blanchard EB. The impact of oncologists behavioron
patient satisfaction with morning rounds.Cancer. 1986;58:387-93.
50. Cohen RE, Blanchard EB, Ruckdeschel JC, Smolen RC. Prevalence and correlates of post-treatment
and anticipatory nausea and vomiting in cancer chemotherapy. J PsychosomRes. 1986;30:643-54.
51. Funa K, Dawson N, Jewett PB, Agren H, Ruckdeschel JC, Bunn Jr PA, Gazdar AF. Automated
fluorescent analysis for drug-induced cytotoxicity assays.Cancer Treat Rep. 1986;70:1147-51.
52. Rodichok LD, Ruckdeschel JC, Harper GR, Cooper G, Prevosti L, Fernando L, Baxter DH. Early
detection and treatment of spinal epidural metastases:the role of myelography. Ann Neurol. 1986;20:696-
702.
53. Mulshine J, Glatstein E, Ruckdeschel JC. Treatment of non-small cell lung cancer [invited review]. J

Clin Oncol.1986;11:1704-15.
54. Blanchard CG, Ruckdeschel JC. Psychosocialaspects ofcancer in adults: implications for teaching
medicalstudents. J Cancer Educ. 1986;1:237-48.
55. Ruckdeschel JC, Carney DN, Oie H, Russell EF, Gazdar AF. In vitro chemosensitivity of human lung
cancer cell lines. Cancer Treat Rep. 1987;71:697-704.
56. Trump DL, Elson P, Borden EC, Harris J, Tuttle R, Whisnant JK, Oken M, Carignan JR, Ruckdeschel
JC, Davis TE.High dose lymphoblastoid interferon in advanced renal cell carcinoma. An Eastern
Cooperative Oncology Group study.Cancer Treat Rep. 1987;71:165-69.
57. Baker RR, Ettinger DS, Ruckdeschel JC, Eggleston JC, McKneally MF, Abeloff MD, Woll JE,
Adelstein DJ. The role of surgery in the management of selected patients with small cell carcinoma of the
lung. J Clin Oncol.1987;5:697-702.
58. Blanchard CG, Ruckdeschel JC, Labrecque MS, Frisch S, Blanchard EB. The impact of a designated
cancer unit on house staffbehaviors toward patients.Cancer. 1987;60:2348-54.
59. Finkelstein DM, Cassileth BR, Bonomi PD, Ruckdeschel JC, Ezdinli EZ, Wolter JM. A pilot study of
the functional living index-cancer (FLIC) scale for the assessment ofquality of life for metastatic lung
cancer patients: an Eastern Cooperative Oncology Group study.Am J Clin Oncol. 1988;11:630-33.
60. Ruckdeschel JC. Whither screening for lung cancer [editorial]. J Natl Cancer Inst.1988;80:78-9.
61. Blanchard CG, Labrecque MS, Ruckdeschel JC, Blanchard EB. Information and decision-making
preferences of hospitalized adult cancer patients.Soc Sci Med. 1988;27:1139-45.
62. Ruckdeschel JC. Attempts to enhance locoregional control of cancer by radiotherapy, phototherapy
and combined modality therapy [invited review]. Curr Opin Oncol. 1989;1:231-5.
63. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC,
Harris J, Comis R, Glick J. Combination chemotherapy versus single agents followed by combination
chemotherapy in stageIVnon-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group
study.J Clin Oncol. 1989;7:1602-13.
64. Ettinger DS, Finkelstein DM, Abeloff MD, Ruckdeschel JC, Aisner SC, Eggleston JC. A randomized
comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no
maintenance therapy for extensive-stage small cell lung cancer: a phase III study of the Eastern
Cooperative Oncology Group. J Clin Oncol.1990;8:230-40.
65. Aisner SC, Finkelstein DM, Ettinger DS, Abeloff MD, Ruckdeschel JC, Eggleston JC. The clinical
significance of
variant-morphology small cell carcinoma of the lung. J Clin Oncol. 1990;8:402-8.
66. Blanchard CG, Labrecque MS, Ruckdeschel JC, Blanchard EB. Physician behaviors, patient
perceptions and patient
characteristics as predictors of satisfaction of hospitalized adult cancer patients.Cancer. 1990;65:186-92.
67. Ettinger DS, Finkelstein DM, Donehower RC, Chang AYC, Greene M, Blum R, Hahn RG,
Ruckdeschel JC. A phase II study of n-methylformamide, spirogermanium and 4-demethoxydaunorubicin
in the treatment of non-small cell lung cancer (EST 3583). An ECOG Study.Med Ped Oncol. 1989;17:197-
201.
68. Braun MA, Killam DA, Remick SC, Ruckdeschel JC. Lung cancer in patients seropositive for human
immunodeficiency virus. Radiology. 1990;175:341-3.
69. Remick SC, Diamond C, Migliozzi JA, Solis O, Wagner H, Haase RF, Ruckdeschel JC. Primary
central nervous systemlymphoma (PCL) in patients with and without AIDS. A retrospective analysis and
review of the literature. Medicine. 1990;69(6):345-60.
70. Ruckdeschel JC. Is chemotherapy for metastatic non-small cell lung cancer “worth it?” [editorial]. J
Clin Oncol. 1990;8:1293-6.
71. Nelles WB, Blanchard CG, McCaffrey RJ, Ruckdeschel JC. Social supports and breast cancer: a
review. J Psychosoc Oncol. 1991;9(2):21-34.
72. Kobassa SCO, Spinetta JJ, Cohen J, Crano WD, Hatchett S, Kaplan BH, Lansky SB, Prout MN,
Ruckdeschel JC, Siegel K, Wellisch DK. Social environment and social support.Cancer. 1991;67 (suppl
1):788-93.
73. Johnson DH, Ruckdeschel JC, Keller JH, Lyman GH, Kallas GJ, MacDonald J, DeConti RC, Lee J. A
randomized trial to compare intravenous and orally administered etoposide in combination with cisplatin
for the treatment of small cell lung cancer. Cancer. 1991;67(suppl):245.
74. Ettinger DS, Finkelstein DM, Abeloff MD, Chang YC, Smith TJ, Oken MM, Ruckdeschel JC. Phase
II study of nmethylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of

advanced small cell lung cancer. Invest New Drugs. 1990;9(2):183-85.
75. Remick SC, Harper GR, Abdullah MA, McSharry JJ, Ross JS, Ruckdeschel JC. Metastatic breast
cancer in a young patient seropositive for human immunodeficiency virus. J Natl Cancer Inst. 1991;83:447.
76. Labrecque MS, Blanchard CG, Ruckdeschel JC, Blanchard EB. The impact of family presence on the
physician cancer patient interaction. Soc Sci Med. 1991;33:1253-61.
77. Remick SC, Ruckdeschel JC. Extrapulmonary and pulmonary small-cell carcinoma: tumor biology,
therapy and outcome. Med Pediatr Oncol. 1992;20:89-99.
78. Ruckdeschel JC, Piantadosi S, and the LCSG. Quality-of-life assessment in lung surgery for
bronchogenic carcinoma. Theor Surg. 1991;6:201-5.
79. Ruckdeschel JC, Moores D, Lee JY, Einhorn LH, Mandelbaum I, Koeller J, Weiss GR, Losada M,
Keller J. Intrapleural therapy for malignant pleural effusions: a randomized comparison of bleomycin and
tetracycline. Chest. 1991;100:1528-35.
80. Henry DH, Beall GN, Benson CA, Carey J, Cone L, Eron LJ, Fiala M, Fischl M, Gabin S, Galpin J,
Gottlieb M, Groopman JE, Hooton T, Jemsek J, Levine R, Miles S, Rinehart JJ, Rios A, Robbins W,
Ruckdeschel JC, Smith J, Spruance S, Starrett B, Toney J, Zalusky R, Abels R, Bryant E, Larholt R,
Sampson A, Rudnick S. Recombinant human erythropoietin in the treatment of the anemia associated with
human immunodeficiency virus infection and zidovudine therapy: overview of four clinical trials. Ann
Intern Med. 1991;117:739-48.
81. Ruckdeschel JC. Chemotherapy of metastatic non-small cell carcinoma of the lung. Hematol Oncol.
1992;10:25-30.
82. Ruckdeschel JC. Special problems in the older cancer patient: spinal cord compression and pleural
effusions. Oncology. 1992;6(2):119-23.
83. Sklarin NT, Wiernik PH, Grove WR, Benson L, Mittelman A, Maroun JA, Steward JA, Robert F,
Doroshow JH, Rosen PJ, Jolivet J, Ruckdeschel JC, Robert NJ, Velez-Garcia E, Bergsagel DE, Panasci
LC, van der Merwe AM, Longueville JJ, Leiby J. A phase II trial of CI-921 in advanced malignancies.
Invest New Drugs. 1992;10:309-12.
84. Ruckdeschel JC, Modi SP, el-Hamouly W, Portuese E, Archer S. N-methylcarbamate derivatives of
ellipticine and olivacine with cytotoxic activity against four human lung cancer cell lines. J Med Chem.
1992;35(26):4854-7.
85. Grossman SA, Ruckdeschel JC, Moynihan T, Finkelstein D, Ettinger DS, Mahoney E, Trump DL.
Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with
previously untreated neoplastic meningitis. J Clin Oncol. 1993;11:561-9.
86. Ruckdeschel JC. Therapeutic options for the treatment of small cell and non-small cell cancer of the
lung. Curr Opin Oncol. 1993;5(2):323-34.
87. Ruckdeschel JC. Cellular characterization of lung cancer - a caveat [editorial]. Chest. 1993;104(2):331.
88. Scott F, Cuttitta F, Treston A, Avis I, Gupta P, Ruckdeschel JC, Kelly K, Piantadosi S, Tockman M,
Mulshine J. Prospective trial evaluating immune-cytochemical-based sputumtechniques for early lung
cancer detection: assays for promotion factors in the bronchial lavage. J Cell Biochem Suppl.
1993;17F:175-83.
89. Maroun J, Ruckdeschel JC, Natale R, Morgan R, Dallaire B, Sisk R, Gyves J. Multicenter phase II
study of brequinar sodium in patients with advanced lung cancer. Cancer Chemother Pharmacol.
1993;21(1):64-6.
90. Remick SC, McSharry JJ, Wolf BC, Blanchard CG, Eastman AY, Wagner H, Portuese E, Wighton T,
Powell D, Pearce T, Horton J, Ruckdeschel JC. Novel oral combination chemotherapy in the treatment of
intermediate-grade and high-grade AIDS-related non-hodgkin’s lymphoma. J Clin Oncol. 1993;11(9):1691-
702.
91. el-Hamouly WS, Ruckdeschel JC, Archer S. Preparation and antitumor activity of an n-
methylcarbamate derivative of amsacrine. Eur J Med Chem. 1993;28:913-6.
92. Tockman MS, Erozan YS, Gupta P, PiantadosiS, Mulshine JL, Ruckdeschel JC, and the LCEDWG
Investigators. The early detection of second primary lung cancers by sputum immune-staining. Chest.
1994;106(6):385s-90s.
93. Lad T, Piantadosi S, Thomas P, Payne D, Ruckdeschel JC, Giaccone G, the LCSG, the Eastern
Cooperative Oncology Group and the European Organization for Research and Treatment of Cancer. A
prospective randomized trial to determine the benefit of surgical resection of residual disease following
response ofsmall cell lung cancer to combination chemotherapy. Chest. 1994;106(6):320s-3s.
94. Ruckdeschel JC, Piantadosi S, for the Lung Cancer Study Group. Quality of life in lung cancer

surgical adjuvant trials. Chest. 1994;106(6):324s-8s.
95. Wagner H, Lad T, Piantadosi S, Ruckdeschel JC, for the Lung Cancer Study Group. Randomized
phase II evaluation of pre-operative radiation therapy and pre-operative chemotherapy with mitomycin-c,
vinblastine, and cisplatin in patients with technically unresectable stage IIIA and IIIB non-small cell cancer
of the lung: LCSG 881. Chest. 1994;106(6):348s-54s.
96. Linnoila RI, PiantadosiS, Ruckdeschel JC, for the Lung Cancer Study Group. Impact of
neuroendocrine differentiation in non-small cell lung cancer: the LCSG experience. Chest.
1994;106(6):367s-71s
97. Shaw GL, Falk RT, DesLauriers J, Nesbitt JC, McKneally MF, Frame JN, Feld R, Issaq HJ,
Ruckdeschel JC, Hoover RN. Lung tumor resection does not affect debrisoquine metabolism. Cancer
Epidemiol Biomarkers Prev. 1994;3:141-4.
98. Ruckdeschel JC. Chemical pleurodesis for malignant pleural effusions: a reply [letter]. Ann Intern
Med. 1994;121(2):150.
99. Remick SC, Reddy M, Herman D, Grace C, Harper G, Willis K, Candon B, Horton J, Ruckdeschel JC.
Continuous infusion bleomycin in AIDS-related kaposi sarcoma. J Clin Oncol. 1994;12(6):1130-6.
100. Ruckdeschel JC. Special report: Lung Cancer Study Group - final analysis. Cancer Control.
1994;1:283-5.
101. Ruckdeschel JC. Lung cancer: time for an end to nihilism. Cancer Control. 1994;2(5):430-1.
102. Ruckdeschel JC, Blanchard C, Albrecht T. Psychosocialoncology research: where we have been,
where we are going and why we won’t get there. Cancer. 1994;74(4):1458-63.
103. Holmes EC, Ruckdeschel JC. Preoperative chemotherapy for locally advanced non-small cell lung
cancer. Semin Oncol. 1994;21:3(6):97-100.
104. McCaffrey RJ, Orsillo SM, Ortega A, Pendry, D., Haase RF, Ruckdeschel JC, WagnerH.
Neuropsychological sequelae of prophylactic cranial irradiation therapy: a prospective study.Assessment
in Rehabilitation and Exceptionality. 1995;2(1):25-33.
105. Wolff AC, Ettinger DS, Neuberg D, Comis RL, Ruckdeschel JC, Bonomi PD, Johnson DH. Phase II
study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung
cancer: an Eastern Cooperative Oncology Group pilot study.J Clin Oncol. 1995;13(7):1615-22.
106. Blanchard CG, Albrecht TL, Ruckdeschel JC, Grant III CH, Hemmick RM. The role of social
support in adaptation to cancer and to survival. J Psychosoc Oncol. 1995;13(1/2):75-95.
107. Remick SC, Chmura M, Bromberg C, Sporn J, Healey B, Hilstro J, DeConti RC, Horton J,
Ruckdeschel JC, Harper GR. Concurrent 72-hour continuous infusion of etoposide and cisplatin in
metastatic breast cancer. Cancer Clin Trials. 1996;19(2):125-31.
108. Stock HS, Rosellini RA, Abrahamsen GC, McCaffrey RJ, Ruckdeschel JC. Methotrexate does not
interfere with an appetitive pavlovian conditioning task in sprague-dawley rats. Physiol Behav.
1995;58(5):969-73.
109. Ruckdeschel JC. Rapid, cost-effective diagnosis of spinal cord compression due to cancer. Cancer
Control. 1995;2(4):320-3.
110. Antonia S, Wagner H, Williams C, Alberts WM, Hubbell, D., Robinson L, Hilstro J, Ruckdeschel JC.
Concurrent paclitaxel/cisplatin with thoracic radiation in patients with non-small cell carcinoma of the lung.
Semin Oncol. 1995;22(4):34-7.
111. Ruckdeschel JC. Management of malignant pleural effusions. Semin Oncol. 1995;22(2):58-63.
112. Ruckdeschel JC, Albrecht T, Blanchard C, Hemmick R. Communication, accrual to clinical trials and
the physician patient relationship: implications for training program. J Cancer Educ. 1996;11(2):73-9.
113. Ruckdeschel JC. Preoperative paclitaxel plus carboplatin for patients with intermediate-risk non-
small cell lung cancer. Semin Oncol. 1996;23(6):62-7.
114. Pisters KMW, Kris MG, Bunn Jr PA, Johnson DH, Ruckdeschel JC, Crowley JJ, Ginsberg RJ.
Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Semin Oncol. 1997;24(4)(suppl
4):41-4.
115. Antonia S, Ruckdeschel JC. Improving our management of NSCLC and mesothelioma [editorial].
Cancer Control. 1997;4(4):293.
116. Tockman MS, Mulshine JL, Piantadosi S, Erozan YS, Gupta PK, Ruckdeschel JC, Taylor PR,
Zhurkov T, Zhou W, Qiao Y, Yas SX. Prospective detection of preclinical lung cancer: preliminary results
from two studies ofhnRNP A2/B1 overexpression. Clin Cancer Res. 1997;3:2237-46.
117. Spiers ASD, Esseltine DLW, Ruckdeschel JC, Davies NP, Horton J. Metastatic adenoid cystic
carcinoma of salivary glands.Case reports and review of the literature. Cancer Control. 1996;3(4):336-42.

118. Blanchard CG, Albrecht TL, Ruckdeschel JC. The crisis of cancer: psychologicalimpact on family
caregivers. Oncology. 1997;11(2):189-94.
119. Larson GP, Zhang G, Ding S, Foldenauer K, Vdar N, Gatti RA, Neuberg D, Lunetta KL, Ruckdeschel
JC, Longmate J, Flanagan S, Krontiris TG. An allelic variant in the ATM locus implicated in breast cancer
susceptibility. Genet Test. 1998;1(3):165-70.
120. Ruckdeschel JC. Slow but real progress in the treatment of thoracic malignancy [editorial review].
Curr Opin Oncol. 1998;10(2):119-21.
121. Ruckdeschel JC, Gridelli C, Perrone F, Monfardini S, Giaccone G. Current controversies in cancer:
are platinum compounds mandatory in the treatment of metastatic non-small cell lung cancer? Pro. Eur J
Cancer. 1998;34(13):1993-9.
122. Remick SC, Sedransk N, Haase R, Craffey M, Subramanian N, Dowlati A, Nazeer T, Ramnes C,
Blanchard C, Mastrianni D, Balducci L, Horton J, Ruckdeschel JC. Oral combination chemotherapy in the
management of AIDS-related lymphoproliferative malignancies. Drugs. 1999;58(3):99-107.
123. Albrecht TL, Blanchard C, Ruckdeschel JC, Coovert M, Strongbow RM. Strategic physician
communication and oncology clinical trials. J Clin Oncol. 1999;17(10):3324-32.
124. Ruckdeschel JC. Update in oncology. Ann Intern Med. 1999;16:131(10):760-7.
125. Yuen AR, Fuks JZ, Ettinger DS, Chang AY, Ruckdeschel JC, Phan SC, Blum RH. Pilot study with
weekly chemotherapy for patients with extensive small cell lung cancer: an Eastern Cooperative Oncology
Group study (PA586). Cancer J Sci Am. 2000;6(1):34-9.
126. Simendinger E, Ruckdeschel JC, Vizzi D. Does e-commerce belong in a cancer & research
institution? J Healthcare Manag. 2000;45:3.
127. Chirikos TN, Ruckdeschel JC, Krischer JP. Impact of clinical trials on the cost of cancer care. Med
Care. 2001;39(4):373-83.
128. Bennett CL, Stinson TJ, Votel V, Robertson L, Leedy D, O’Brien P, Hobbs J, Sutton T, Ruckdeschel
JC, Chirikos TN, Weiner RS, Ramsey MM, Wicha MS. Evaluating the financial impact of clinical trials in
oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern
University clinical trials costs and charges project. J Clin Oncol. 2000;18(15):2805-10.
129. Kilbridge KL, Cole BF, Kirkwood JM, Haluska FG, Atkins MA, Ruckdeschel JC, Sock DE, Nease Jr
RF, Weeks JC: Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alfa-2B for high-
risk melanoma patients using intergroup clinical trial data. J Clin Oncol. 2002;20(5):1311-8.
130. Chirikos TN, Ruckdeschel JC, Krischer JP. Economic analysis of cancer treatment costs:anothertool
for oncology managers. J Oncol Mgmt. 2001;10(3):11-17.
131. Jacobsen PB, Meade CD, Stein KD, Chirikos TN, Small BJ, Ruckdeschel JC. Efficacy and costs of
two forms of stress management training for cancer patients undergoing chemotherapy. J Clin Oncol.
2002;20:2851-62.
132. Riddle DL, Albrecht TL, Coovert MD, Penner LA, Ruckdeschel JC, Blanchard CG, Quinn G, Urbizu
D. Differences in audiotaped versus videotaped physician – patient interactions. J Nonverbal Behavior.
2002;26:219-39.
133. Albrecht TL, Ruckdeschel JC, Ray III FL, Pethe BJ, Riddle DL, Strohm J, Penner LA, Coovert MD,
Quinn G, Blanchard CG. A portable, unobtrusive device for videorecording clinical interactions. Behav Res
Methods.2005;37(1):165-9.
134. Albrecht TL, Ruckdeschel JC, Riddle DL, Blanchard CG, Penner LA, Coovert MD, Quinn G.
Communication and consumer decision making about cancer clinical trials. Patient Educ Couns.
2003;50:39-42.
135. Albrecht TL, Penner LA, Ruckdeschel JC. Understanding patient decisions about clinical trials: a
proposed theoretical model and associated methodologies to examine the process.J Cancer Educ.
2003;18:210-4.
136. Simon GR, Ruckdeschel JC, Williams C, Cantor A, Chiappori A, Rocha Lima CM, Antonia S, Haura
E, WagnerH, Robinson L, Sommers E, Alberts M, Bepler G. Gefitinib (Iressa, ZD1839) in previously
treated advanced non-small cell lung cancer. Experience from a single institution. Cancer Control.
2003;10:388-95.
137. Larson GP, Ding Y, Cheng LSC, Lundberg C, Gagalang V, Rivas G, Geller L, Weitzel J, MacDonald
D, Archambeau J, Slater J, Neuberg D, Daly MB, Angel I, Benson III AB, Smith K, Kirkwood JM,

O'Dwyer PJ, Raskay B, Sutphen R, Drew R, Stewart JA, Werndli J, Johnson D, Ruckdeschel JC, Elston
RC, Krontiris TG. Genetic linkage of prostate cancer risk to the chromosome 3 region bearing FHIT.
Cancer Research. 2004;65: 805-814.
138. Quinn GP, Jacobsen PB, Albrecht TL, Ellison BAB, Newman NW, Bell M, Ruckdeschel JC. Real-
time patient satisfaction survey and improvement process.Hosp Top. 2004;82(3):26-32
139. Ruckdeschel JC. Fatigue is becoming an exhausting problem [editorial]. Cancer. 2005;103(2):213-5.
140. Albrecht TL, Ruckdeschel JC, Ray FL 3rd,Pethe BJ, Riddle DL, Strohm J, Penner LA, CoovertMD,
Quinn G, Blanchard CG. A portable, unobtrusive device for video recording clinical interactions. Behav
Res Methods 2005, 37(1):165-9.
141. Ruckdeschel JC. The problem of lung cancer as a paradigm-keynote address.Ethnicity Dis. 2005;
15(suppl 1):S1-2.
142. Ruckdeschel JC. Early detection and treatment of spinal cord compression. Oncology. 2005;
19(1):81-92.
143. Albrecht TL, Franks MM, Ruckdeschel JC. Communication and informed consent.Curr Opin Oncol.
2005;17:336-9.
144. Cote ML, Kardia SL, Wenzlaff AS, Ruckdeschel JC, Schwartz AG. Risk of lung cancer among white
and black relatives of individuals with early lung cancer. JAMA; 2005;293(24): 3036-42.
145. Eggly S, Penner L, Albrecht TL, Cline RJW, FosterT, Naughton M, Peterson A, Ruckdeschel, JC.
Discussing 'bad news' in the outpatient oncology clinic: rethinking current communication guidelines. J
Clin Oncol. 2006,
24(4):716-719.
146. Schwartz AG and Ruckdeschel JC. Familial lung cancer: genetic susceptibility and relationship to
chronic obstructive pulmonary disease.Am J Respir Crit Care Med. 2006; 173(1): 16-22.
147. Ruckdeschel JC. Second line chemotherapy for non-small cell lung cancer. Chest 2006; 129(4):840-2
148. Albrecht TL, Kuerer H, Ruckdeschel JC, Mendez J, Harper F, American College of Surgeons
Oncology Group. Transdisciplinary studies of surgical oncology trial accrual: A National Institute of
Health/ National Cancer Institute Roadmap-affiliated project update. Cancer. 2006; 107(1): 171-4.
149. Eggly S, Penner LA, Greene M, Harper FW, Ruckdeschel JC, Albrecht TL. Information seeking
during “bad news” oncology interactions: Question asking by patients and their companions. Soc Sci Med.
2006; 63(11): 2974-85.
150. Robinson LA, Ruckdeschel JC, WagnerH Jr, Stevens CW. Treatment of non-small cell lung cancer-
stage IIIA; ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007, 132(3Suppl):
243S-265S.
151. Paterson A., Cline R., FosterT, Jones E, Penner L, Parrott R,. Keller C, Naughton M, Taub J,
Ruckdeschel JC, Albrecht T. Parent’s interpersonal distance and touch behavior and child pain and
distress:Journal of Nonverbal Behavior 2007;31: 79-97.
152. Penner L, Orom H, Franks M, Albrecht T, FosterT, Ruckdeschel JC. Camera-related behaviors during
video recorded medical interactions: Journal of Nonverbal Behavior 2007;31: 99-117.
153. Cline RJW, Penner LA, Harper FWK, FosterTS, Ruckdeschel JC, Albrecht T. Patients’ Internet use
for cancer information and socioeconomic status as co-advantages in oncologist-patient communication.
Journal of Oncology Practice. 2007; 3: 167-171.
154. Gadgeel SM, Ruckdeschel JC, Heath EL, Heilbrun LK, Venkatramanamoorthy R, Wozniak A. Phase
II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and
celecoxib a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung
cancer (NSCLC). J Thorac Oncol. 2007;2(4): 299-305.
155. Eggly, S., Albrecht, T.L., Harper, F.W.K., Foster, T.,., Franks, M.M., Ruckdeschel, JC. Oncologists’
recommendation of clinical trial participation to patients.Patient Education and Counseling. 2008;
70(1):143-8.
156. Albrecht, T.L., Eggly S.S., Gleason M.E., Harper F.W., Foster T.S., Petereson A.M., Orom H, Penner
L.A., Ruckdeschel JC. Influence of clinical communication on patients’decision making on participation
in clinical trials. J Clin Oncol. 2008; 26(16): 2666-73.
157. Gadgeel SM, Wozniak A, Ruckdeschel JC, Heilbrun LK, Venkatramanamoorthy R, Chaplen RA,
Kraut MJ and Kalemkerian GP. Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in
elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer. J Thor Oncol.
2008; 3:1293-300.
158. Whitehouse AC, Black CB, Heppe MS, Ruckdeschel JC, Levin SM. Environmental exposure to

Libby Asbestos and mesotheliomas. Am J Ind Med. 2008; 51:877-80.
159. Schwartz AG, Cote ML, Wenzlaff AS, Van Dyke A, Chen W, Ruckdeschel JC, Gadgeel S, Soubani
A. Chronic obstructive lung diseases and risk of non-small cell lung cancer. J Thorac Oncol 2009; 4: 291-9.
160. Albrecht TL, Eggly SS, Penner LA, Cline RJW, Ruckdeschel JC. Studying the Process of Clinical
Communication: Issues ofContext, Concepts and Research Directions. J Health Commun. 2009; 14
Suppl1: 47-56.
161. Pena T, LoRusso PM, Ruckdeschel JC, Goncalves P, Soubani AO. Pulmonary metastasis of basal cell
carcinoma: a rare manifestation of a common disease with variable clinical course. J Thorac Oncol. 2009;
4:1026-7.
162. Gleason ME, Harper FW, Eggly S, Ruckdeschel JC, Albrecht TL. The influence of patient
expectations regarding cure on treatment decisions.Patient Educ Couns.2009;75:263-9. Epub 2009 Jan 14.
163. Wang Y, Rishi AK, Puliyappadamba VT, Sharma S, Yang H, Tarca A, Dou QP, Lonardo F,
Ruckdeschel JC, Pass HI, Wali A. Targeted proteasome inhibition by Velcade induces apoptosis in human
mesothelioma and breast cancer cell lines. Cancer Chemother Pharmacol. 2010:66:455-66.
164. Schneider BJ, Kalemkerian GP, Ramnath N, Kraut MJ, Wozniak AJ, Worden FP, Ruckdeschel JC,
Zhang X, Chen W, Gadgeel SM. Phase II trial of imatinib maintenance therapy after irinotecan and
cisplatin in patients with c-Kitpositive, extensive-stage small-cell lung cancer. Clin Lung Cancer. 2010;
11:223-7.
165. Cline RJ, Orom H, Berry-Bobovski L, Hernandez T, Black CB, Schwartz AG, Ruckdeschel JC.
Community-level social support responses in a slow-motion technological disaster: the case of Libby,
Montana.AM J Community
Psychol. 2010; 46: 1-18.
166. Turner JT, Khoury JD, Ruckdeschel JC. Granulomatous Solitary Pulmonary Nodule. J Bronchol
Intervent Pulmonol. 2011; 18:111.
167. Soubani AO, Ruckdeschel JC, The outcome of medical intensive care for lung cancer patients: the
case for optimism. J Thorac Oncol, 2011; 6:633-8.
168. Gadgeel SW, Ruckdeschel JC, Patel, BB, Wozniak A, Konski A, Valdivieso M, Hackstock D, Chen
W, Belzer K, Marquette L, Turrisi A. Phase II study of pemetrexed and cisplatin, with chest radiotherapy
followed by docetaxel in stage III non-small cell lung cancer (NSCLC) patients.J Thorac Oncol 2011: 6;
927-33.
169. Northouse LL, Mood DW, Schafenacker A, Kalemkerian G, Zalupski M, LoRusso P, Hayes DF,
Hussain M, Ruckdeschel JC, Fendrick MA, Trask PC, Ronis DL, Kershaw T. Randomized clinical trial of
a brief and extensive dyadic intervention for advanced cancerpatients and their family caregivers. Psycho-
Oncology 2013;22: 555-63.
170. Karp DD, Lee SJ, Keller SM, Wright GS, Aisner S, Belinsky SA, Johnson DH, Johnston M,Goodman
G, Clamon G,Okawara G, Marks R, Frechette E, McCaskill-Stevens W, Lippman SM, Ruckdeschel JC,
and Khuri FR. A Randomized, Double Blind, Placebo-Controlled, Phase III Chemoprevention Trial of
Selenium Supplementation in Persons with Resected Stage I Non Small Cell Lung Cancer (ECOG 5597) J.
Clin Oncol2013, 31:4179-85.
171. Krug LM, Wozniak AJ, Kindler HL, Feld R, Koczywas M, Morero JL, Rodriguez C, Ros HJ, Bauman
JE, Orlov SV, Ruckdeschel JC, Mita AC , Fein L, He X, Hall HR, Kawabe T, Sharma S. Randomized
Phase II Trial of Pemetrexed/Cisplatin with or without CBP501 in Patients with Advanced Malignant
Pleural Mesothelioma Lung Cancer. 2014 Sep; 85(3):429-34.
172. Hahn EE, Tang T, Lee JS, Munoz-Plaza C, Adesina O, Shen E, Rowley B, Maeda JL, Mosen DM,
Ruckdeschel JC, Gould M.Use of advanced imaging for staging of early breast cancer in two
integrated health care systems:Adherence with a Choosing Wisely Recommendation. Submitted J Oncol
Practice 2014
BOOK CHAPTERS, LETTERS, MONOGRAPHS, SYMPOSIA REPORTS
1. Ruckdeschel JC. Tumor registries [letter]. JAMA. 1973;266-72.
2. Ruckdeschel JC. Case records of the Massachusetts General Hospital [invited discussion].N Engl J
Med.1974;291:1297-1303.
3. Ruckdeschel JC, Wiernik PH. Reactions to radiation therapy [letter]. N Engl J Med. 1975;293:668-9.
4. Ruckdeschel JC. Amantadine and pulmonary peripheral airways [letter]. Ann Int Med. 1977;86:369-70.
5. Ruckdeschel JC, Lininger L, Brzyski H, Miani M, Becker J. Re-analysis of in vitro lymphocyte
blastogenesis using the laser cytometry assay.In: Baum S, editor. Experimental hematology today.

Farmington, CT: Karger; 1979.p.123-8.
6. Ruckdeschel JC. Diagnosis and management of small cell anaplastic (oat cell) cancer of the lung.
Current concepts in oncology.1979;1:18-24.
7. Ruckdeschel JC. Lung cancer - mediguide to oncology. 1981;1(6).
8. Ruckdeschel JC. Early diagnosis of lung cancer [editorial]. Clinical Cancer Briefs. 1981;2:2.
9. Ruckdeschel JC. Immunotherapy of Human Cancer: An Overview. In: Schimpff S, Moossa AR,
Robson MC, eds.Comprehensive Textbook of Oncology. Baltimore: Willliams and Wilkins Publishers;
1984.
10. Ruckdeschel JC, Balint J, Gross P, Laufer F. Instructionalcosts for full-time faculty in an academic
department of internal medicine. In: Hurst W, editor. Teaching internal medicine. 1984.
11. Ruckdeschel JC, Blanchard CG, Blanchard EB. Direct measurement of physician behavior as a
potential method of evaluating medical education. In: Hurst W, editor. Teaching internal medicine. 1984.
12. Muggia FM, Goldin A, Ruckdeschel JC. New drugs in lung cancer. Proceedings of the 4th
Mediterranean Congress of Chemotherapy; 1984 Oct 19-25; Rhodes, Greece. Chemioterapia. 1984;4(2
Suppl):1138-9.
13. Ruckdeschel JC, Oie HK, Gazdar AF. In vitro characterization of non-small cell lung cancer. In:
Hansen HH,Nijhoff M, editors. Lung cancer: basic and clinical aspects.Boston:Kluwer; 1986. p. 49-59.
14. Ruckdeschel JC. Chemotherapy in metastatic lung cancer: Reply [letter]. J Clin Oncol. 1986;4:1151-2.
15. Ruckdeschel JC. Chemotherapy of non-small cell lung cancer. In: Kimura K, Ota K, Heberman RB,
Takita H, editors. Cancer chemotherapy: challenges for the future, vo. 2. pp 202-209, Eds. K. Kimura, K.
Ota, R.B. Heberman, H. Takita. Tokyo: Excerpta Medica; 1987. p 202-209.
16. Ruckdeschel JC. Management of malignant pleural effusions.Semin Oncol. 1988;15(3 suppl3):24-8.
17. Ruckdeschel JC, Moores D. Malignant pleural effusions: diagnosis and management [monograph,
video]. NewYork, NY: LP Communications; 1988.
18. Ruckdeschel JC. Chemotherapy of disseminated non-small cell lung cancer. In Bitram J, Golomb H,
editors. Lung cancer: a comprehensive treatise. New York, NY: Grune & Stratton; 1988. p 233-41.
19. Ruckdeschel JC. Clinical advances in management of malignant pleural effusions.J Crit Illn. 1988.
20. Ruckdeschel JC, Moores D. Non-small cell lung cancer: a multimodality approach to treatment
[monograph, video]. New York, NY: LP Communications, 1989.
21. Ruckdeschel JC. Lung cancer: an introduction. In: Roth J, Ruckdeschel J, WeisenburgerT, editors.
Textbook of Thoracic Oncology. Philadelphia, PA: WB Saunders; 1989. p 2-5.
22. Mulshine J, Ruckdeschel JC. The role of chemotherapy in the management of disseminated non-small
cell lung cancer. In: Roth J, Ruckdeschel J, WeisenburgerT, editors. Textbook of thoracic oncology.
Philadelphia, PA: WB Saunders; 1989. p 220-8.
23. Blanchard CG, Ruckdeschel JC. Quality of life. In: Roth J, Ruckdeschel J, Weisenburger T, editors.
Textbook of Thoracic Oncology. Philadelphia, PA: WB Saunders; 1989. p. 681-6.
24. Ruckdeschel JC. Book review: Arriagada R, LeChevalier T, editors. Treatment modalities in lung
cancer. J Natl
Cancer Inst. 1989; 8:633-4.
25. Ruckdeschel JC, Moores D. MPE II: recent findings in the clinical management of malignant pleural
effusions [monograph, video]. New York: LP Communications; 1990.
26. Ruckdeschel JC. Etoposide in the management of non-small cell lung cancer. Cancer.
1991;67(suppl):250.
27. Ruckdeschel JC, editor. Malignant pleural effusions:recent advances in diagnosis and management.
Bristol-Myers Squibb; 1992.
28. Ruckdeschel JC, Holmes EC. Preoperative chemotherapy for locally advanced non-small cell lung
cancer. In: Pass H, editor. Chest Clinics of North America. 1991;1:1-12.
29. Holmes EC, Ruckdeschel JC. Postoperative chemotherapy for non-small cell lung cancer. In: Pass H,
editor. Chest Clinics of North America. 1991;1(1):89-97.
30. Ruckdeschel JC. “Current surgical approach to non-small cell lung cancer” by McCormack P [invited
commentary]. Oncology. 1991;5(11):44-6.
31. Ruckdeschel JC. Comprehensive textbook of oncology [review]. J Natl Cancer Inst. 1992;84:1596-7.
32. Moffett MJ, Ruckdeschel JC. Bleomycin and tetracycline in malignant pleural effusions.Semin Oncol.
1992;19(suppl):59-62.
33. Ruckdeschel JC. A comparative overview of non-small cell lung cancer: 1980 v 1991. Lung cancer.
1993;9(suppl):15-24.

34. Remick SC, WagnerH, Ruckdeschel JC. Management of the patient with HIV-associated lymphomas
and hodgkins disease.AIDS reader. 1991;1:204-13.
35. Ruckdeschel JC. Lung cancer - 1993. Mediguide to oncology.1994;14(1):1-8.
36. Ruckdeschel JC. The role of standard dose etoposide in the management of non-small cell lung cancer.
Semin Oncol. 1992;19(6):39-44.
37. Wagner H, Ruckdeschel JC. Treatment of locally advanced and metastatic non-small cell lung cancer.
Advances in Oncology. 1993;9(5):22-9.
38. Ruckdeschel JC. Preoperative and postoperative adjunctive therapy for resectable non-small cell lung
cancer. In: Roth J, Cox J, Hong WK, editors. Lung cancer. Boston: Blackwell Scientific Publications; 1993.
p. 239-51.
39. Ruckdeschel JC. The future role of carboplatin. Semin Oncol. 1994;21(5):114-8.
40. Ruckdeschel JC. Spinal cord compression due to cancer: early diagnosis and treatment. In: Abeloff M,
Armitage J, Lichter A, Niederhuber J, editors. Clinical oncology.New York: Churchill Livingstone; 1995.
p. 619-28.
41. Ruckdeschel JC. Carcinoma of the lung current therapy. In: Rakel R, editor. Conn’s current therapy.
Philadelphia: WB Saunders; 1994. p.156-63.
42. Ruckdeschel JC, Robinson LA. Non-small cell lung cancer: surgery and postoperative adjuvant
chemotherapy. In: Pass H, Mitchell D, Johnson A,Turrisi J, editors. Lung cancer: principles & practice.
Philadelphia: JB Lippincott; 1996. P.839-49.
43. Ruckdeschel JC. Current status and future role of carboplatin [monograph]. Bristol-Myers Squibb,
1994.
44. Ruckdeschel JC. Future directions in non-small cell lung cancer-a personalview. Lung cancer.
1995;12(2):s147- 52.
45. Ruckdeschel JC. Lung cancer: an overview. In: Roth J, Ruckdeschel J, Weisenburger T, editors.
Thoracic Oncology II. Philadelphia: WB Saunders; 1995. p.3-4.
46. Williams C, Ruckdeschel JC. Management of disseminated non-small cell lung cancer. In: Roth J,
Ruckdeschel J, Weisenburger T, editors. Thoracic Oncology II. Philadelphia: WB Saunders; 1995. p.181-7.
47. Moores D, Ruckdeschel JC. Pleural effusions in patients with malignancy. In: Roth J, Ruckdeschel J,
WeisenburgerT, editors. Thoracic Oncology II. Philadelphia: WB Saunders; 1995. p.556-66.
48. Wagner H, Ruckdeschel JC. Screening, early detection and early intervention strategies for cancer of
the respiratory system(lung and bronchus).In: Reintgen D, Clark RA, editors. Cancer screening. St. Louis:
Mosby Year Book; 1995. p.118-49.
49. Ruckdeschel JC. The cost of success in the treatment of thoracic malignancies [commentary]. Curr
Opin Oncol. 1995;7:131-3.
50. Blanchard C, Ruckdeschel JC, Albrecht T. Patient-family communication with physicians.In: Bader,
Cooper, DeNour, editors. Cancer and the family. West Sussex : John Wiley & Sons; 1996. p.369-87.
51. Ruckdeschel JC. Introduction: LCSG - the final analysis.Chest. 1994;106(6):279s.
52. Ruckdeschel JC, Aisner J, Ettinger DS, Johnson DH, Wagner H. Small cell lung cancer [monograph].
Bristol Myers Squibb, 1995.
53. Ruckdeschel JC. Malignant effusions in the chest.In: Kirkwood JM, Lotze MT, Yasko JM, editors.
Current cancer therapeutics.2nd ed. Philadelphia: Churchill-Livingstone; 1996. p.304-8.
54. Ruckdeschel JC. We have met the enemy . . . and they is us![commentary]. Curr Opin Oncol.
1996;8:103-5.
55. Ruckdeschel JC. Malignant pleural effusion: a cost-effectiveness analysis ofpleurodesis [monograph].
56. Ruckdeschel JC, Wagner H, Robinson L. Locally advanced lung cancer - controversies in
management. ASCO Educational Book, 1996.
57. Ruckdeschel JC, Wagner H, Robinson L. Locally advanced lung cancer: controversies in management.
Advances in Oncology. 1996;12(3):22-8.
58. Ruckdeschel JC, Wagner H, Robinson L. Cáncer de Pulmón Localmente Avanzado [Locally
Advanced Lung Cancer] (Spanish). Revista argentina cancerología.1996;24(2):90-2.
59. Ruckdeschel JC. Breaking clinical and administrative barriers. In: Semendinger, editor. The challenge
of health care leadership. Chicago: AHA Publishing; 1997. p.51-68.
60. Ruckdeschel JC, Robinson L. Malignant pleural effusions: questions and controversies [monograph].
61. Ruckdeschel JC. Combined modality therapy of non-small cell lung cancer. Semin Oncol.

1997;24(4):429-39.
62. Robinson L, Ruckdeschel JC. Management of pleural and pericardial effusions. In: Berger, Portenoy,
Weissman, editors. Lung cancer: principles and practice of supportive oncology.Philadelphia: JB
Lippincott; 1998. p.327-52.
63. Ruckdeschel JC. Treating lung cancer. Coping. 1997;38-9.
64. Antonia S, Robinson LA, Ruckdeschel JC, WagnerH. Lung cancer. In: Balducci, Lyman, Ersher,
editors. Comprehensive geriatric oncology.2nd ed. London: Harwood Academic Publishers; 1997. p.613-
30.
65. Ruckdeschel JC. Editorial overview: lung and mediastinum. Curr Opin Oncol. 1997;9(2):147-8.
66. Bonomi P, Ruckdeschel JC. New approaches in the treatment of stage IV non-small cell lung cancer
[monograph]. Bristol Myers Squibb, 1997.
67. Ruckdeschel JC. IASLC proceedings - future directions in non-small cell lung cancer: a continuing
perspective [review]. Oncology. 1998;12(2):90-6.
68. Ruckdeschel JC. Preoperative and postoperative adjunctive therapy for resectable non-small cell lung
cancer. In: Roth JA, Cox JD, Hong WK, editors. Lung Cancer. 2nd ed. Boston: Blackwell Scientific; 1997.
p.207-16.
69. Garland LL, Ruckdeschel JC, Wagner Jr H, Williams Jr C, Shaw G, Antonia S, Heise M, Hilstro J,
Cantor A. Single agent paclitaxel as second-line chemotherapy for resistant,metastatic non-small cell lung
cancer. In: Johnson, Klastersky, editors. Taxanes in lung cancer therapy. New York: Marcel Dekker, Inc.;
1998. p.117-26.
70. Ruckdeschel JC, Aisner J, Ettinger D, Jett J, Wagner H. Current approaches to managing patients with
small cell lung cancer [monograph]. Smith Kline Beecham, 1997.
71. Ruckdeschel JC. A prospective randomized trial of bleomycin vs doxycycline vs talc for the
intrapleural treatment of malignant pleural effusions. In: Jett J, editor. Current clinical trials in thoracic
oncology - what the chest
physician needs to know. 1997;1(3).
72. Ruckdeschel JC. Malignant effusions in the chest.In: Kirkwood JM, Lotze MT, Yasko JM, editors.
Current Cancer Therapeutics,3rd ed. New York: Churchill Livingstone; 1998. p.324-8.
73. Ruckdeschel JC, Aisner J, Evans W, Gandara D, Green M, Holmes EC, Ihde DC, Johnson DH, Sause
WT, Wagner Jr H. Commentary and review of presentations on lung cancer [monograph]. Bristol Myers
Squibb, 1998.
74. Mackey CS, Ruckdeschel JC. Lung cancer. In: Sullivan P, Guilford AM, editors. Swallowing
Intervention in Oncology. San Diego: Singular Publishing; 1999. p.117-33.
75. Ruckdeschel JC. Chemotherapy for lung cancer: new agents with significant benefit. Primary Care &
Cancer. 1998;18(5):26-32.
76. Ruckdeschel JC. Spinal cord compression. In: Abeloff M, Armitage J, Lichter A, Niederhuber J,
editors. Clinical Oncology. 2nd ed. New York: Churchill Livingstone; 1999. p.811-9.
77. Tockman M, Ruckdeschel JC, Mulshine J. The early detection of second primary lung cancers by
sputum immunostaining. In: Jett J, editor. Current clinical trials in thoracic oncology - what the chest
physician needs to know. 1998;2(1):3,8-9.
78. Yanes B, Bonomi PD, Curran Jr WJ, Ginsberg RJ, Khuri FR, Ruckdeschel JC, Weiland JE. Advances
in lung cancer management: 1997 Miami Valley hospitallung conference [monograph]. Bristol Myers
Squibb, 1998.
79. Ruckdeschel JC. Myths and facts about lung cancer: What You Need to Know. Melville (NY): PRR
Publishers; 1999.
80. Blanchard C, Albrecht T, Ruckdeschel JC. Patient family communication with physicians.In: Bader,
Cooper, DeNour, editors. Cancer and the family. 2nd ed. West Sussex(England): John Wiley & Sons,Ltd;
2000. p.477-95.
81. Ruckdeschel JC. Intrapleural therapy.In: Ratain MJ, Tempero M, Skosey C, editors. Oncology
therapeutics:a quick reference guide. Philadelphia: WB Saunders; 2000.
82. Simon G, Ginsberg R, Ruckdeschel JC. Small cell lung cancer. Chest Surg Clin N Am.
2001;11(1):165-8.
83. Ruckdeschel JC, Robinson L. Management of pleural and pericardial effusions. In: Berger, Portenoy,
Weissman, editors. Lung cancer ; principles and practice of palliative care and supportive oncology.
Philadelphia: Lippincott,Williams & Wilkins. In press 2001.
84. Ruckdeschel JC, Jablons D. Malignant effusions of the chest.In: Kirkwood JM, Lotze MT, Yasko JM,

editors.Current Cancer Therapeutics.4th ed. Philadelphia: Current Medicine; 2001.
85. Ruckdeschel JC. Myths and facts about lung cancer: What You Need to Know. Melville (NY): PRR
Publishers; 2002.
86. Robinson LA, WagnerH, Ruckdeschel JC. Lung cancer guidelines, treatment of stage IIIA non-small
cell lung cancer. Chest. 2003;123(suppl 1): 3325-75.
87. Albrecht TA, Blanchard CG, Ruckdeschel JC, Coovert MA. The mediating role of communication in
cancer treatment decision making. In: Brashers D, Goldsmith D, and Lammers L, editors. Communication
in the management of health and illness. Manwah (NJ): Lawrence Erlbaum & Associates.In press.
88. Ruckdeschel JC, Greene J, Sommers KE, Fields KK. Respiratory complications of cancer and its
treatment. In: Kufe DW, Holland JF, Frei E, editors. Cancer Medicine 6. Hamilton (ON); Lewiston (NY)
[distributor]: BC Decker. 2003.
89. Alberts WM, Bepler G, Hazelton T, Ruckdeschel JC, Williams Jr JH. Lung cancer. Practice
organization. Chest. 2003;123(suppl 1):2202-5.
90. Ninane V, LePechoux C, Curran W, Furuse K, Liptay M, Meert AP, Paesmans M, Rami-Porta R,
Roelandts R, Ruckdeschel JC, Sculier JP, Senan S, Smit EF. Critical factors for patient management. Lung
Cancer. 2003;42(suppl):57-8.
91. Ruckdeschel JC, guest editor. Update in the management of lung cancer. New York (NY): RogersMIS.
2004;3(2).
92. Ruckdeschel JC. Spinal cord compression [book chapter]. In: Abeloff M, Armitage J, and Niederhuber
J, editors. Clinical Oncology. Philadelphia: Churchill-Livingstone; 2004. p.1063-71.
93. Ruckdeschel JC. Lung cancer [book chapter]. In: Abeloff M, Armitage J, and Niederhuber J, editors.
Clinical Oncology. Philadelphia: Churchill-Livingstone; 2004. p.1649-743.
94. Ruckdeschel JC. Myths and facts about lung cancer. What You Need to Know. Melville (NY): PRR
Publishers; 2004.
95. Helft PR, Albrecht TL, Back A, Ruckdeschel JC. Challenges to physician communication about
treatment options to patients.ASCO Educational Book Alexandria: American Society of Clinical
Oncology; 2006
96. Ruckdeschel JC. At the Core of Oncology (book chapter) In: The Art and Science of Oncology.
Boston (MA): Aspatore Books; 2007. pp33-44.
ABSTRACTS
1. Ruckdeschel JC, Wiernik PH. Carcinoembryonic antigen in patients with hematologic malignancies
[abstract].USAEC Report Conf. 1974;73:1141.
2. Ruckdeschel JC, Graziano KD, Mardiney Jr MR. Parameters of in vitro lymphocyte responsiveness to
measles antigen [abstract]. Fed Proc. 1974;33:619.
3. Ruckdeschel JC, Doukas J, Mardiney Jr MR. Direct, quantitative analysis of in vitro lymphocyte
responsivenessto antigen,mitogen and allogeneic cells using a new laser based cell sizing apparatus
[abstract]. Fed Proc. 1975;34:995.
4. Ruckdeschel JC, Schimpff SC, Dunmire C, Smyth AC, Wiernik PH, Mardiney Jr MR. Correlation of
susceptibility to herpes zoster with impaired cell associated immunity to the varicella zoster virus in
patients with hodgkin’s disease
[abstract]. Clin Res. 1975;23:311A.
5. Ruckdeschel JC, Martin RG, Byhardt RW. Nonradiotherapeutic factors in the development of radiation
related pericardial effusions in patients treated for hodgkin’s disease [abstract]. Proc ASCO. 1975;16:238.
6. Ruckdeschel JC, Dunmire C, Mardiney Jr MR. Cell associated immunity to measles in SSPE. Evidence
for impaired lymphocyte transformation in response to measles antigen [abstract]. Arch Neurol.
1975;32:497.
7. Ruckdeschel JC, Doukas J, Mardiney Jr MR. Application of laser cytometry to the analysis of
immunologically induced in vitro lymphocyte responsiveness [abstract].Clin Res. 1975;23:585A.
8. Jones III PP, Ruckdeschel JC, Eckert C, Horton J. Management of rectal villous adenomas with
particular reference to the high incidence of associated colonic malignancies [abstract]. Clin Res.
1977;25:408A.
9. Ruckdeschel JC, Lininger L, Brzyski H, Miani M, Becker J. Re-analysis of in vitro lymphocyte
blastogenesis using the laser cytometry assay [abstract]. Exp Hematol. 1978;6:70.

10. Caradonna R, Paladine W, Goldstein J, Ruckdeschel JC, Hillinger S, Horton J. Combination
chemotherapy with high dose cis-diamine dichloroplatinum, methotrexate and bleomycin for epidermoid
carcinoma of the head and neck
[abstract]. Proc Am Assoc Cancer Res. 1978;19:401.
11. Ruckdeschel JC, Horton J, McKneally MF. Cytoxan, adriamycin, methotrexate and procarbazine
(CAMP) in the management of bronchogenic carcinoma [abstract]. Proc ASCO. 1978;19:378.
12. Ruckdeschel JC, Becker JR, Miani MA, Lininger L, Brzyski H. Sequential analysis of cell-associated
immunity (CAI) by laser cytometry [abstract]. Fed Proc. 1978;37(6):1843.
13. Ruckdeschel JC, McSharry J, Caliguiri L, Horton J. Cellular basis of cancer medicine: an integrated
approach to the clinical and biological aspects of oncology [abstract]. Fed Proc. 1978;37(6):1548.
14. Ferraro J, Lansing L, Ruckdeschel JC. Giant cell cancer of the lung: a rapidly fatal histologic variant
[abstract]. Proc ASCO. 1979;20:405.
15. Lunia SL, Ruckdeschel JC, McKneally MF, Killam D, Baxter D, McIlduff JB, Ray P, Chodos R,
Horton J. Mediastinal involvement by bronchogenic carcinoma: correlation of chest radiography, gallium
scanning and surgical biopsy [abstract]. Proc ASCO. 1979;20:405.
16. Brzyski H, Konchanin L, Baustin A, Ruckdeschel JC. Abnormal mitogen induced lymphocyte
proliferation in patients with lung cancer: possible role of the surface modulating assembly [abstract]. Proc
AACR. 1979;20:148.
17. Ruckdeschel JC, Brzyski H. Dissociation of blast transformation and radionucleotide incorporation by
agentsinterfering with surface modulating assembly activity [abstract]. Clin Res. 1979;27:335A.
18. Ruckdeschel JC, McKneally MF, Devore C, Baxter D, Sedransk N, Caradonna R, Horton J. Regional
immunotherapy fails to improve response to combined radiation and chemotherapy in patients with stage
III non-oat cell bronchogenic carcinoma confined to the thorax: a controlled comparison [abstract]. Proc
ASCO/AACR. 1980;21:374.
19. Harper GR, Rodichok LD, Ruckdeschel JC, Price A, Sedransk N, Horton J. Early Detection of Spinal
Epidural Metastases [abstract].Proc ASCO/AACR. 1980;21:189.
20. Cohen RE, Blanchard C, Rohrbaugh M, Horton J, Ruckdeschel JC. Physician attitudes towards cancer:
variations based on experience and specialty [abstract]. Proc ASCO/AACR. 1980;21:383.
21. Brandman J, Ruckdeschel JC, O’Donnell M, Horton J, Harrington G. Unexpected pulmonary
complications of intensive therapy for small cell cancer of the lung (SCCL) [abstract]. Proc ASCO/AACR.
1980;21:459.
22. Ferraro J, Hillinger S, O’Donnell M, McNamee R, Ruckdeschel JC, Horton J. Treatment of advanced
large bowel cancer with m-AMSA. A GITSG pilot study [abstract].Proc ASCO/AACR. 1980;21:420.
23. Weissman CH, Ruckdeschel JC, Ferraro J, Reilly C, Horton J. Cyclophosphamide, adriamycin and
VP-16-213 (CAVP-16) chemotherapy in the management of advanced non-oat cell bronchogenic
carcinoma (NOBC) [abstract]. Proc ASCO/AACR. 1980;21:459.
24. Ruckdeschel JC, Creech R, Mehta C. Chemotherapy of advanced non-oat cell bronchogenic
carcinoma: the Eastern Cooperative Oncology Group experience [abstract]. In: Hansen H, Dombernowsky,
editors. Abstracts II world conference on lung cancer. Princeton (NJ): Excerpta Medica; 1980. p.237.
25. McKneally MF, Maver C, Bennett J, Ruckdeschel JC. Evaluation of regional BCG in lung cancer
[abstract]. In: Hansen H, Dombernowsky, editors. Abstracts II world conference on lung cancer. Princeton
(NJ): Excerpta Medica; 1980. p.108.
26. Ruckdeschel JC, Harper GR, Rodichok LD. Early diagnosis of spinal epidural metastases [abstract].
Clin Res. 1980;28:652A.
27. Cohen R, Ruckdeschel JC, Blanchard C, Last C, Horton J. Adaptation to mastectomy: variation based
on time from surgery and use of adjuvant chemotherapy [abstract]. Abstract Medical and Pediatric
Oncology 8:424, 1980.
28. O'Donnell M, Ruckdeschel JC, Sedransk N, Baxter D, Spiers A, Horton J. Does intensive induction
chemotherapy improve survival in small cell cancer of the lung (SCCL)?: a randomized comparison
[abstract]. Proc ASCO/AACR. 1981;22:168.
29. Ruckdeschel JC, Filardi HG, Konchanin L, Wiener G, Sedransk N. S/G2 arrest: an alternate
mechanism for diminished lymphocyte proliferation in patients with cancer [abstract]. Proc ASCO/AACR.
1981;22:319.
30. Cohen RE, Sheehan AP, Ruckdeschel JC, Blanchard EB, Hall VI, Poleto MA, Cassidy MH, Horton J.
Patient and treatment factors in the development of chemotherapy-related nausea and vomiting [abstract].
Proc ASCO/AACR. 1981;22:418.

31. Horton J, Eyerson W, Baxter D, Ruckdeschel JC. Post operative radiation (RT) for rectal cancer is not
always innocuous [abstract]. Proc ASCO/AACR. 1981;22:414.
32. Blanchard CG, Ruckdeschel JC, Saunders NL, Malloy D, Horton J. The measurement of physician
behavior on inpatient rounds [abstract].Med Ped Oncol. 1981;9:567.
33. Ruckdeschel JC, Blanchard CG, Cohen RE. Assessment ofattitudes toward cancer [abstract]. Med Ped
Oncol. 1981;9:452-3.
34. Ruckdeschel JC, Blanchard CG, Saunders N, Malloy ED, Blanchard E, Horton J. Patient-physician
interactions: the measurement of physician behavior on inpatient oncology rounds [abstract]. Proc ASCO.
1982;1:49.
35. Ahles T, Blanchard EB, Ruckdeschel JC, Sheehan AP. Assessing the multidimensional aspects of
cancer-related pain: toward a practical assessment package [abstract]. Proc ASCO. 1982;1:49.
36. Harper GR, Rodichok LD, Prevosti L, Lininger L, Ruckdeschel JC. Early diagnosis of spinal epidural
metastases leads to improved treatment outcome [abstract]. Proc ASCO. 1982;1:6.
37. Ruckdeschel JC, Mason B, Ettinger D, Creech R, Mehta C, Stanley K. Failure to define a "standard"
chemotherapy for metastatic non-small cell bronchogenic carcinoma [abstract]. Proc AACR. 1982;23:39.
38. Ruckdeschel JC, Mason B, Ettinger D, Creech R, Mehta C, Stanley K. Chemotherapy of metastatic
non-oat cell bronchogenic carcinoma: the Eastern Cooperative Oncology Group experience [abstract]. In
Secretariat, editor. Abstracts III World Conference on Lung Cancer. Proceedings of the 3rd World
Conference on Lung Cancer; 1982 May 17-20; Tokyo, Japan. p.185.
39. Blanchard CG, Ruckdeschel JC, Blanchard EB, Arena J, Saunders N, Malloy D. Do attitudes predict
behavior? Correlation of oncologists'attitudes with their observed behavior toward cancer patients
[abstract]. Med Pediatr Oncol. 1982;10:49A.
40. Spiers ASD, Ruckdeschel JC, Horton J, Rauch AE, O'Donnell MR, Burkart PT. Effectiveness of
pentostatin (2' deoxycoformycin, DCF) in refractory lymphoid neoplasms [abstract]. Blood.
1982;60(1):163a.
41. Ruckdeschel JC, Zimmerman MS, Hussain M. Chemotherapy-induced interstitial pneumonitis during
treatment of small cell anaplastic lung cancer [abstract]. Proc ASCO. 1983;2:199.
42. Bonomi P, O'Reilly W, Vogl S, Ruckdeschel JC, Creech R, Stolbach L. A phase II trial of
cyclophosphomide,VP16 and methotrexate in small cell bronchogenic carcinoma (SCBC): an Eastern
Cooperative Oncology Group pilot study [abstract].Proc ASCO. 1983;2:199.
43. Berenzweig M, Vogl S, Camacho F, Ruckdeschel JC. Esophageal squamous cancerchemotherapy
(CT) with methylglyoxal bis-guanylhydrazone (MGBG), methotrexate (M), bleomycin (B) and
diamminedichloroplatinum (D) - "MGBG-MBD" [abstract]. Proc ASCO. 1983;2:125.
44. Blanchard CG, Ruckdeschel JC, Blanchard EB, Murray S, Pallmeyer TP, Fried K. The relationship
between physician behavior on inpatient oncology rounds and patient satisfaction [abstract]. Med Pediatr
Oncol. 1983;11:43A-44A.
45. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Mason BA, Vogl SE, Joss RA. Chemotherapy of
metastatic nonsmall cell bronchogenic carcinoma (NSCBC): a randomized comparison of the four most
active regimens [abstract]. Proc AACR. 1984;25:171.
46. Armstrong M, Harper G, Line B, Ruckdeschel JC. Dual isotope technique for in vitro quantitative
assessment ofintra-arterial (IA) drug delivery to hepatic metastases [abstract].Proc AACR. 1984;25:169.
47. Harper G, Cooper L, Baxter D, Fernando L, Ruckdeschel JC. Value of myelography (MG) for
planning treatment (RT) of spinal epidural metastases (SEM) [abstract]. Proc ASCO. 1984;3:72.
48. Blanchard CG, Ruckdeschel JC, Blanchard EB, Fletcher BA. Patient satisfaction with specific
behaviors of medical oncologists during inpatient rounds [abstract]. Proc ASCO. 1984;3:72.
49. Bunting N, Bonomi P, O'Reilly W, Vogl S, Creech R, Ruckdeschel JC, Stolbach L, Ettinger D.
Prognostic factors in patients with small cell bronchogenic carcinoma treated on an eastern cooperative
oncology group phase II trial [abstract]. Proc ASCO. 1984;3:228.
50. Ruckdeschel JC, Finkelstein DM, Creech RH, Ettinger DS. Chemotherapy of metastatic non-small cell
bronchogenic carcinoma [abstract]. Clin Res. Apr 1984.
51. Blanchard CG, Ruckdeschel JC, Fletcher BA, Blanchard EB. Predictors of high and low patient
satisfaction on inpatient oncology rounds [abstract].Med Pediatr Oncol. 1984;12:24A.
52. Line BR, Harper GR, Armstrong M, Ruckdeschel JC. Dual isotope technique for in vivo quantitative
assessment ofintra-arterial (IA) drug delivery to hepatic metastases [abstract].J Nucl Med. 1984;25:41.
53. Ettinger DS, Baker RR, Eggleston JC, Abeloff MD, Ruckdeschel JC, McKneally MF, Woll J,
Adelstein D. Prospective evaluation of the role of surgery in limited disease (LD) small cell lung cancer.

An Eastern Cooperative Oncology Group pilot study [abstract].Proc ASCO. 1985;4:180.
54. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Mason BA, Vogl SE, Joss RA. Predictors of improved
response and survival in metastatic non-small cell bronchogenic carcinoma (NSCBC) [abstract]. Proc
ASCO. 1985;4:187.
55. Ruckdeschel JC, Gazdar AF, Carney DN, Russell EF, Oie H. The use of human lung cancer cell lines
for in vitro chemosensitivity testing [abstract]. Proc AACR. 1985;26:367.
56. Gazdar AF, Oie H, Russell E, Carney DN, Linnoila J, Ruckdeschel JC, et al. Establishment and
characterization of a large comprehensive panel of cell lines demonstrates the diversity of human lung
cancer [abstract]. Proc AACR. 1985;26;27.
57. Ruckdeschel JC, Finkelstein DM, Ettinger DS. Chemosensitivity of metastatic non-small cell lung
cancer (NSCLC) [abstract]. Proc. IV World Conference on Lung Cancer; 1985 Aug 25-30; Toronto,
Canada.
58. Ruckdeschel JC, Gazdar AF, Carney DN, Russell EF, Oie H. In Vitro chemosensitivity testing for
human non-small cell lung cancer: the role of cell lines [abstract]. Proc. IV World Conference on Lung
Cancer; 1985 Aug 25-30; Toronto, Canada.
59. Blanchard CG, Fletcher BA, Ruckdeschel JC, Frisch S, Blanchard EB, Brady AC. The measurement
of house staff interactions with cancer and non-cancer patients [abstract]. Med Pediatr Oncol. 1985;13:14A.
60. Wagner H, Ruckdeschel JC, Bonomi P, Danjux C, Richter M, Ettinger D. Treatment of locally
advanced non-small cell lung cancer (NSCLC) with mitomycin C, vinblastine and cis-DDP (MVP)
followed by radiation therapy (RT): an Eastern Cooperative Oncology Group pilot study [abstract]. Proc
ASCO. 1985;4:183.
61. Ettinger DS, Mehta CR, Abeloff MD, Ruckdeschel JC, Aisner S. A randomized comparison of
conventionalchemotherapy with immediate alternation of non-cross resistant chemotherapy in extensive
disease (ED) small cell lung cancer (SLCLC) [abstract]. Proc ASCO. 1986;5:170.
62. Bennett JA, Ruckdeschel JC, Riley K, Kaye-Wenzel M. Differential chemosensitivity of lewis lung
carcinoma (LLC) to cyclophosphamide (CYT) and doxorubicin (DOX): accurate prediction by the subrenal
capsule (SRC) and novel dye exclusion (NDE) assays [abstract].Proc AACR. 1986;27:413.
63. Ruckdeschel JC, Riley K. In vitro chemosensitivity of human cancer cell lines to 4-hydroperoxy-
cyclophosphamide (4HC), melphalan (M), phosphoramide mustard (PM) and nitrogen mustard (NM)
[abstract]. Proc AACR. 1986;27:411.
64. Labrecque MS, Blanchard CG, Ruckdeschel JC, Blanchard EB. The impact of cancer patient decision-
making preferences on patient satisfaction [abstract]. J Cancer Educ. 1986;1(3):213.
65. Ruckdeschel JC, Riley K. Dose-dependent cytotoxicity of etoposide in human lung cancer cell lines:
role of thesolvent carrier [abstract]. Proc AACR. 1987;28:425.
66. Ettinger DS, Mehta CR, Abeloff MD, Ruckdeschel JC, Aisner S. Maintenance chemotherapy versus
no maintenance chemotherapy in complete responders following induction chemotherapy in extensive
disease (ED) small cell lung cancer (SCLC) [abstract]. Proc ASCO. 1987;6:175.
67. Bonomi P, Mehta C, Ruckdeschel JC, Blum R, Mason B, Greene M. Phase II-III trial of mitomycin-
vinblastinecisplatin (MVP); vinblastin-cisplatin (VP); MVP alternating with cyclophosphamide-
adriamycin-methotrexateprocarbazine (MVP/CAMP); CBDCA followed by MVP; and CHIP followed by
MVP in patients with metastatic non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology
Group study [abstract]. Proc ASCO. 1987;7:177.
68. Aisner SC, Ettinger D, Finkelstein D, Ruckdeschel JC, Mehta C, Abeloff M, Eggleston J. The clinical
significance of variant morphology (small cell/large cell) small cell carcinoma of the lung (SCCL)
[abstract]. Proc ASCO. 1988;7:A752.
69. Fudin J, DeConti R, Ruckdeschel JC. Chemical phlebitis due to CI-921: The role of formulation/
dissolution characteristics [abstract]. Proc AACR. 1989;30:A968.
70. Ruckdeschel JC, Piantadosi S. Assessment ofquality of life (QL) by the functional living index-cancer
(FLIC) is superior to performance status for prediction of survival in patients with lung cancer [abstract].
Proc ASCO. 1989;8:A1209.
71. Ruckdeschel JC, Archer S. Rational design of a novel ellipticine derivative with significant activity
against human lung cancer cell lines [abstract]. Proc AACR. 1989;30:A2420.
72. Ruckdeschel JC, Moores D, Lee J, Einhorn L, Mandelbaum J, Koeller J, Weiss G, Losada M, Keller J.
Management of malignant pleural effusions (MPE): a randomized comparison of tetracycline and
bleomycin [abstract]. Proc ASCO. 1990;9:323.
73. Moores D, Ruckdeschel JC, Lee J, Einhorn L, Mandelbaum I, Koeller J, Weiss G, Losada M, Keller J.

Malignant pleural effusion: a randomized comparison of tetracycline and bleomycin [abstract]. Chest.
1990;98(2):44.
74. Wagner Jr H, Lad T, Ruckdeschel JC. Randomized phase I comparison of preoperative radiation
therapy (XRT) and chemotherapy with mitomycin-C, vinblastine and cisplatin for patients with pathologic
stage IIIA and IIIB non-small cell lung cancer (NSCLC) [abstract]. Proc ASTRO. 1990 Oct.
75. Diamond C, Remick S, Migliozzi J, Solis O, WagnerH, Haase R, Ruckdeschel JC. Primary central
nervous systemlymphoma (PCL) in patients with and without acquired immunodeficiency syndrome
(AIDS) [abstract]. Proc ASCO.
1990;9:A367.
76. Ross JS, Samaan S, Ruckdeschel JC, Wagner H. DNA ploidy in atypical carcinoid tumors of the lung
[abstract]. Lab Invest.1991;64(1):118A.
77. Ruckdeschel JC, Archer S, Cioli D, Portuese E. Antitumor properties of some n-methylcarbamates
derived from ellipticine and olivacine [abstract]. Proc AACR. 1991;32:2412.
78. Remick S, McSharry J, Wolf B, Blanchard C, Gorman P, Slaga J, Wagner H, Harper G, Horton J,
Ruckdeschel JC. Novel oral combination chemotherapy (CT) in the management of AIDS-related non-
hodgkin's lymphoma (NHL) [abstract]. Proc ASCO. 1991;10:32.
79. Bromberg C, Remick S, Harper G, Sporn J, Healey B, Hilstro J, von Roemeling R, Horton J,
Ruckdeschel JC. Concurrent 72-hour continuous infusion (CI) of etoposide (VP-16) and cisplatin (DDP)
in metastatic breast cancer [abstract]. Proc ASCO. 1991;10:49.
80. Grossman SA, Ruckdeschel JC, Moynihan T, Finkelstein D, Ettinger D, Mahoney E, Trump D.
Randomized prospective comparison of intraventricular (IT) methotrexate (MTX) and thiotepa (TT) for
neoplastic meningitis (NM) [abstract]. Proc ASCO. 1991;10:127.
81. Moore M, Robert F, Cripps F, Ruckdeschel JC, Neidhart J, Natale R, Dallaire B, Gyves J. A phase II
study of brequinar sodium (DuP 785, NSC 368390) in gastrointestinal(GI) cancers (ca) [abstract]. Proc
ASCO. 1991;10:152.
82. von Roemeling R, Fisher H, DeConti R, Horton J, Wilbur H, Hrushesky W, Ruckdeschel JC.
Continuous FUDR infusion for hormone refractory prostate cancer: A phase I/II study [abstract].Proc
ASCO. 1991;10:171.
83. Ruckdeschel JC, Linnoila RI, Mulshine JL, Kim K, Aisner S, Gazdar AF, Jensen SM, Bonomi P. The
impact of neuroendocrine (NE) and epithelial (EPI) differentiation on response and survival in lung cancer:
the ECOG experience [abstract]. Proc ASCO. 1991;10:248(A849).
84. Linnoila RI, Ruckdeschel JC, Piantadosi S, Jensen SM, Mulshine JL. The impact of neuroendocrine
(NE) and epithelial (EPI) differentiation on recurrence and survival in patients (pts) with resected non-
small cell lung cancer (NSCLC): the LCSG experience [abstract]. Proc ASCO. 1991;10:248(A850).
85. Maroun J, Ruckdeschel JC, Natale R, Morgan R, Robert F, Berkowitz I, Dallaire B, Wilgosz G. A
phase II study of brequinar sodium (DuP 785, NSC 368390) in lung cancers [abstract]. Proc ASCO.
1991;10:A850.
86. Bonomi P, Finkelstein D, Chang A, Ruckdeschel JC. Decreasing response rates in eastern cooperative
oncology group (ECOG) stage IV non-small cell lung cancer (NSCLC) trials: comparison of sequential
studies [abstract].Proc ASCO. 1991;10:261.
87. Hisington S, Remick S, MacDowell R, Hilstro J, Ramnes C, Izqierdo R, Harper G, Ruckdeschel JC.
Venous access via a peripherally implanted device: a preliminary trial [abstract]. Proc ASCO. 1991;10:327.
88. Ruckdeschel JC, Linnoila RI, Mulshine JL, Kim K, Piantadosi S, Aisner S, Jensen SM, Gazdar AF for
the Eastern Cooperative Oncology Group and Lung Cancer Study Groups. The impact of neuroendocrine
and epithelial
differentiation on recurrence and survival in patients with lung cancer [abstract]. Sixth World Conference
on Lung Cancer; 1991 Nov 10-14; Melbourne, Australia. Lung Cancer. 1991;7 (suppl):56.
89. Doroshow J, Ruckdeschel JC, Freytes C, Robert F, Havlin K, Adams D, Sisk R, Dallaire B, Gyves J.
A phase II study of DUP 937 in head and neck cancer [abstract]. Proc ASCO. 1992;11:247.
90. von Roemeling R, DeConti R, Horton J, Remick S, Harper G, Hrushesky W, Ruckdeschel JC.
Toxicity of circadian FUDR infusion: a randomized phase I pilot study [abstract].Chronobiology:
Mechanisms and Therapeutic Applications; 1991; Paris, France.
91. Wagner Jr H, Ruckdeschel JC, Williams C, Heise M, Hilstro J. Single agent taxol (Tax) as second-line
chemotherapy for patients with metastatic non-small cell lung cancer (NSCLC) [abstract]. Lung Cancer.
1994;11(suppl 1):120.
92. Ruckdeschel JC, Wagner Jr H, Williams C, Heise M, Hilstro J. Second-line chemotherapy for resistant,

metastatic, non-small cell lung cancer (NSCLC): the role of taxol (Tax) [abstract]. Proc ASCO.
1994;13:A1200.
93. Farrell P, Horton J, Ruckdeschel J, Simon J, Cohen G. A national education program in oncology for
physicians - role of a new medical journal [abstract]. J Cancer Educ. 1994;9(3):A17.
94. Ruckdeschel JC, Albrecht TL, Blanchard C, Hemmick RM. Communication strategies for accruing
patients to clinical trial: implications for training programs [abstract]. Proceedings of the AACE 30th
Annual Meeting; 1995. p.A70.
95. Wolff AC, Ettinger DS, Neuberg D, Comis R, Ruckdeschel JC, Bonomi PD, Johnson DH. A phase II
study ofifosfamide, carboplatin and oral etoposide (ICE) chemotherapy for extensive disease small cell
lung cancer: an Eastern Cooperative Group study [abstract].Proc ASCO. 1994;3:A1198.
96. Ruckdeschel JC, Pattern SG, Cutherbertson DD, Murtagh FR, Arrington JA. Spinal cord compression
in lung cancer. MRI as the first diagnostic test is more cost effective [abstract]. Lung Cancer.
1997;18(1):A826.
97. Wagner H, Antonia SJ, Williams C, Alberts M, Hubble D, Robinson L, Hilstro J, Ruckdeschel JC,
Shaw G. Concurrent paclitaxel/cisplatin (PC) with thoracic radiation (TR) in patients with stage IIIA/B
non-small cell lung cancer (NSCLC) [abstract]. Proc ASCO. 1997;16:A1610.
98. Robinson LA, Ruckdeschel JC. Induction chemotherapy in pleural mesothelioma precludes the
technical performance of an extrapleural pneumonectomy [abstract]. 4th International Mesothelioma
Conference; 1997 May 13- 15; p.47.
99. Krontiris TG, Larson GP, Weitzel JN, Benson AB, Daly MB, DeVore RF, Kirkwood JM, Lunetta KL,
Neuberg DS, O’Dwyer PJ, Ruckdeschel JC, Wagner H, Stewart JA. Mapping interactive cancer
susceptibility loci (eastern cooperative oncology group) [abstract]. Proc ASCO. 1998;17:A2147.
100. Jiroutek M, Johnson D, Blum R, Bonomi P, Chang A, Ettinger D, Ruckdeschel J, Schiller J, Sandler
A. Prognostic factors in advanced non-small cell lung cancer (NSCLC): analysis of eastern cooperative
oncology group (ECOG)
trials from 1981-1982 [abstract]. Proc ASCO. 1998;17:A1774.
101. Garland LL, WagnerH, Shaw GS, Williams CC, Anatonia SA, Khoor A, Meulemans LM, Nimmons
KA, Ruckdeschel JC. Phase I dose-escalation study of constant rate infusion gemcitabine in combination
with taxotere in advanced non-small cell lung cancer [abstract]. Proc ASCO. 1998;17:A1864.
102. Chirikos T, Ruckdeschel JC. Some predictors of the cumulative costs of lung cancer care [abstract].
Proc ASCO. 1999;A1946.
103. Garland LL, WagnerJr HJ, Shaw GS, Williams CC, Antonia SA, Muelemans LM, Nimmons KA,
Ruckdeschel JC. Phase I study of constant dose rate infusion gemcitabine with taxotere in advanced non-
small cell lung cancer [abstract]. Proc ASCO. 1999;A1632.
104. Garland L, Khoor A, Grendys E, Fiorica J, Walsh F, Alberts W, Role M, Anderson W, Ruckdeschel J.
Utility of thyroid transcription factor-1 (TTF-1) in differentiating pulmonary adenocarcinoma from ovarian
or primaryperitoneal adenocarcinoma in women with malignant pleural effusion (MPE) [abstract]. Proc
ASCO. 2000;19:548a.
105. Wright D, Garland L, Wagner H, Clark R, Hazelton T, Shaw G, Antonia S, Williams C, Alberts WM,
Ruckdeschel JC. MRI imaging of the spine is superior to bone scintigraphy in diagnosis of spine
metastases in patients with nonsmall cell lung cancer (NSCLC) [abstract]. Proc ASCO. 2000;19:503a.
106. Stinson TJ, Bennett CL, Vogel V, Lewedy D, Jobbs J, Ruckdeschel JC, Chirikos TN, Weiner RS,
Wicha MS. A multi-center study ofthe costs ofenrolling cancer patients on phase II clinical trials
[abstract]. Proc ASCO. 2000;19:A1695.
107. Sullivan DM, Rago R, Ruckdeschel JC, Dellaportas AM, Mahany JJ, Lush RM, Dalton WS,
Bulanhagui C, Gupta E, Tarby C, Sonnichsen D, Gustafson N, Gallant G. Phase I and pharmacokinetic
study of BMS-188797, a new taxane analog, given every three weeks in patients with advanced
malignancies [abstract]. ERSOTC. 2000.
108. Ruckdeschel JC. Malignant pleural effusions [abstract]. Lung Cancer. 2000;29(2):123.
109. Sullivan DM, Mahany JJ, Tetteh LF, Ruckdeschel JC, Williams CC, Antonia SJ, Lush RM, Sun S-L.
A phase I study of combination therapy with oral 9-nitrocamptothecin and oral etoposide [abstract].
Submitted 2001.
110. Ruckdeschel JC, Spitz M, Saxman S. Summary report of the national cancer institute progress review
group for lung cancer [abstract]. Lung Cancer 2001;34(suppl 1):S7-S8.
111. Ruckdeschel JC, Simon G, Antonia S, Haura E, Williams C, Wagner H, Rocha Lima C, Ettienne K,
Vaughn J, Bepler G. ZD1839 (‘Iressa’) as a single agent for the treatment of metastatic non-small-cell lung

cancer [abstract]. Proc ASCO. 2002.
112. Nordquist L, Simon GR, Alberts WM, Ruckdeschel JC. Improved survival in never smokers versus
current smokers with primary adenocarcinoma of the lung [abstract]. Proc ASCO. 2002.9
113. Riddle DL, Albrecht TL, Coovert MD, Penner LA, Quinn G, Ruckdeschel JC, Blanchard CE.
Observer video probased coding: emperical evidence of value added [abstract]. Measuring Behavior. 2002.
114. Eggly S, Albrecht T, Penner L, Cline R, Ruckdeschel JC, Berkely S, FosterT, Naughton M, Peterson
A. “I know it’s bad, but how bad is it?” Challenges to current guidelines for communication bad news in
the outpatient oncology clinic [abstract]. Medical Encounter. 2004;18.
115. Quinn GP, Jacobsen PB, Wells NL, Peredo C, Albrecht TL, Ruckdeschel JC, Bell M. Real-time
patient satisfaction survey and improvement process [abstract].Psychooncology.2004;13(suppl 1):S29.
116. Franks M, Eggly S, Figueroa M, Hendriks M, Foster T, Ruckdeschel JC, Albrecht T. Physician
communication and patient intention to accrue to cancer clinical trials [abstract]. Cancer Epidemiology,
Biomarkers & Prevention. 2005;14;S2738.
117. Penner L, Franks M, Albrecht T, Foster T, Ruckdeschel JC. Using Noldus Observer® to Assess the
Reactivity of Video Recordings of Medical Interactions [abstract]. Measuring Behavior. 2005.
118. Cline R, Harper F, Penner L, Albrecht T, Ruckdesche JC, Peterson A, Jones E, Taub J, Simon L.
Who’s in the room? Relationships between parents’ communication and children’s stress during painful
cancer treatment procedures [abstract]. Annals of Behavioral Medicine. 2005;29;S38.
119. Greene M, Eggly S, Penner L, FosterT, Albrecht T, Rehan S, Ruckdeschel JC. Patient and
companion questions during discussions ofbad news in oncology interactions [poster]. APOS. 2005.
120. Penner L, Cline R, Jones E, Taub J, Ruckdeschel JC, Albrecht T. Dispositional and affective
correlates of treatment related pain among pedicatric cancer patients [abstract]. Annals of Behavioral
Medicine. 2006;30
121. Penner L, Cline R, FosterT, Jones E, Penner Taub J, Ruckdeschel JC, Albrecht T. Indirect support:
Effects of multiple caregivers on nonverbal immediacy experienced by children during painful pediatric
oncology procedures[abstract].Annals of Behavioral Medicine. 2006;30.
122. Cline R, Jones E, Peterson A, Penner L, Taub J, Ruckdeschel JC, Albrecht T,. Verbal combat: Risks
of invalidating children’s experiences during painful oncology procedures [abstract]. Annals of Behavioral
Medicine. 2006;30.
123. Eggly S, Franks M, Hendriks M, Figueroa M, Foster T, Ruckdeschel JC, Albrecht T. Frequency and
context of oncologist’recommendations regarding clinical trials [abstract]. Annals of Behavioral Medicine.
2006;30.
124. Eggly S, Harper F, Penner L, FosterT, Rana J, Osborn D, Ruckdeschel JC, Albrecht T.
Patient/companion information seeking during offers of clinical trials [abstract]. Annals of Behavioral
Medicine. 2007; 33;S098.
125. Harper F, Gleason M, Eggly S, Ruckdeschel JC, Albrecht T. Expectations about cure, physician-
patient communication, and treatment decision-making in cancer patients [abstract]. Annals of Behavioral
Medicine. 2007;33;S097.
126. Rizvi N, Kris, M, Miller V, Azzoli C,Krug L, Bekele S,Chaplen R, Ruckdeschel J, Gadgeel S. A
pahse II study of XL647 in non small cell lung cancer (NSCLC) patients enriched for presence of EGFR
mutations. J Thor Oncol. 2007; 2(8) S737.
127. Karp DD, Lee S, Shae G, Johnson D, Kucuk O, Clamon G, Marks R, Johnston M,Okawara G,
Ruckdeschel J. Progress Report: Eastern Cooperative Oncology Group (ECOG) E5597, an intergroup
phase III randomized trial of selenium supplementation in resected stage I non small cell lung cancer. J
Thor Oncol. 2007; 2(8) S811.
128. Gadgeel SM, Ruckdeschel JC, Wozniak A, Patel B, Heilbrun LK, Chen W, Venkat R, Chaplen R,
Turrisi A. Pemetrexed and cisplatin with concurrent thoracic radiation therapy (TRT) followed by
Docetaxel in stage III nonsmall cell lung cancer (NSCLC) patients.J Clin Oncol; 2008:26(15S): 414s.
129. Gleason ME, Harper FW, Eggly S, Ruckdeschel JC, Albrecht TL. The influence of patient and
companion cure expectations on treatment decisions. J Clin Oncol 2008; 26(15S): 518s.
130. Eggly S, Harper F, Penner L, FosterT, Austin T, Ruckdeschel J, Albrecht T. Information seeking by
patients and companions during cancer clinical interactions. Psycho-Oncology.2008; 17: S1163.
131. Gadgeel SM, Ruckdeschel JC, Wozniak AJ, Chen W, Hackstock D, Galasso C, Burger A, Ivy SP,
LoRusso P, Edelman MJ. Cebiranib, a VEGF receptor 1,2 and 3 inhibitor, and pemetrexed in patiens (pts)
with recurrent nonsmall cell lung cancer (NSCLC). ASCO Annual Meeting. 2011; Abstract #77915.
132. Krug LM, Wozniak AJ, Kindler HL, Feld R, Koczywas M, Morero JL, Rodriguez CP, Ross HJ,

Bauman JE, Orlov SV, Ruckdeschel JC, Mita AC, Fein L, Fernandez C, Hall R, Kawabe T, and Sharma S.
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced
malignant pleural mesothelioma (MPM). ASCO AnnualMeeting 2012 Abstract 96454
133. Krug LM, Wozniak AJ, Kindler HL, Feld R, Koczywas M, Morero JL, Rodriguez CP, Ross HJ,
Bauman JE, Orlov SV, Ruckdeschel JC, Mita AC, Fein L, Fernandez C, Hall R, Kawabe T, and Sharma S.
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced
malignant pleural mesothelioma (MPM). International Mesothelioma Research Group 2012 Abstract 223.
134. Ruckdeschel JC, Sause WT, Belnap T, Jones C, Rowley, B. Oncology quality improvement as a
cornerstone of the transition to accountable care J Clin Oncol 30, 2012 (suppl 34 abst 141).
135. Sause WT, Ruckdeschel JC, Belnap TW, Jones C, Rowley BD. Building success in quality
improvement: An analysis of what barriers hinder and what catalysts promote the widespread adoption of
quality improvement initiatives. J Clin Oncol 30, 2012 (suppl 34, abst 122).
136. Belnap TW, Sause WT, Rowley,BD, Jones C, Ruckdeschel JC. The role, use, and nuances of clinical
data systems in oncology quality improvement. J Clin Oncol 30, 2012 (suppl34, abst 135).
137. Sause WT, Rees WV, Ruckdeschel JC, Jones CW, Rowley BD, Pena K. Evolution of quality to value
added care in a large healthcare organization. J Clin Oncol 31, 2013 In Press.
138. Ruckdeschel JC, Rees WV, Parkinson BT, Belnap T, Rowley BD, Pena K. The impact of screening
mammography in women 40-49 years of age as a function of tumor biology. J Clin Oncol 31, 2013 In Press.
139. Pillai NR, Lee SJ, Karp DD, AisnerS, Ruckdeschel JC, Ramalingam S, and Khuri FR. Second
Primary Lung Cancers:Analysis of E5597 Selenium Chemoprevention Study. J Clin Oncol: 2014
140. Hahn EE, Tang T, Lee JS, Munoz-Plaza C, Adesina O, Shen E, Rowley B, Maeda JL, Mosen DM,
Ruckdeschel JC, Gould M. Use of advanced imaging for staging of early breast cancer in two
integrated health care systems:Adherence with a Choosing Wisely Recommendation. J Clin Oncol 2015.

CURRICULUM VITAE 2015

Recommended

Recommended

More Related Content

What's hot

What's hot (19)

Viewers also liked

Viewers also liked (20)

Similar to CURRICULUM VITAE 2015

Similar to CURRICULUM VITAE 2015 (20)

CURRICULUM VITAE 2015